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Abstract 
 
Determining the effects of phosphorylation 
on AFAP-110 function. 
 
Lidia N. Cherezova 
 
AFAP-110 was discovered in late eighties as a 110-kDa protein that associates 
with active Src in Src transformed cells. Since then it has been determined that AFAP-
110 is a actin cross-linking protein with an intrinsic ability to remodel actin cytoskeleton 
in response to signals from active Src and PKC. AFAP-110 associates with Src via SH2 
and SH3 interactions and with PKC via amino terminal PH domain. AFAP-110 binds 
actin filaments directly, multimerizes via carboxy-terminal leucine zipper motif and also 
possesses an intrinsic ability to remodel actin cytoskeleton. Therefore AFAP-110 may act 
as a cellular effector for Src and PKC remodeling actin filaments in response to activation 
of these kinases. AFAP-110 is hyperphosphorylated on serine and threonine residues in 
active Src expressing cells and in cells subjected to PMA treatment in PKC-dependent 
manner. PKC-dependent phosphorylation influences AFAP-110 multimerization mode as 
well as its actin-cross linking abilities. Therefore it became important to identify 
functional serine/threonine phosphorylation sites of AFAP-110. 
As there are over twenty potential PKC phosphorylation sites in AFAP-110 
structure, deletional mutagenesis was employed to determine which regions of AFAP-
110 are most likely to contain crucial sites for PKC phosphorylation. Our data indicate 
that functional PKC phosphorylation sites must be localized to the amino acid stretch 
266-294 within STK region of AFAP-110. There are four PKC candidate 
phosphorylation sites in this region; they are being substituted by alanine residues in 
order to determine their significance in serine/threonine phosphorylation regulation of 
AFAP-110 function. 
Analysis of AFAP-110 amino acid sequence has also revealed that AFAP-110 
contains twelve potential 14-3-3 binding sequences. 14-3-3 proteins are a family of small 
acidic adaptor proteins of dimeric nature that act as molecular scaffolds and/or allosteric 
regulators in a number of cellular pathways. We have been interested to determine 
whether 14-3-3 is a binding partner for AFAP-110 in vivo. We determined that AFAP-
110 associates with 14-3-3 in vivo, although it still remains unknown whether this 
association is direct or facilitated by any of a multitude of 14-3-3 binding partners. 
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I.  Introduction. 
Phosphorylation of proteins is a reversible form of posttranslational modification 
that occurs rapidly in response to cellular signals to regulate protein function. 
Phosphorylated proteins often display conformational changes and/or altered ability to 
interact with binding partners. Until recently tyrosine phosphorylation regulated protein-
protein interactions were the subject of thorough investigation while the sole 
consequence of serine/threonine phosphorylation were thought to be allosteric 
modifications. In the past few years it became apparent that serine/threonine 
phosphorylation regulates protein-protein interactions not only via allosteric mechanism, 
but also results in their ability to form complexes with phospho-serine/threonine specific 
binding partners. Four phospho-serine/threonine binding domains that have been 
identified are described below.  
14-3-3 ligand binding groove was the first phospho-serine/threonine specific 
binding domain to be identified (1). It represents a carboxy-terminal part of the 14-3-3 
molecule with highly conserved residues lining the inner surface of a concave ligand-
binding groove (2). Co-crystallization studies have confirmed the phosphorylation 
specific nature of 14-3-3-ligand interactions (3).  Most well-known consensus sequences 
for 14-3-3 conserved binding groove are RSXpS/TXP and RXSXpS/TXP. Arginine in –3 
or –4 position relative to phosphorylated serine or threonine is required, whereas serine in 
–2 and proline in +2 are preferable. Serine or threonine in position 0 must be 
phosphorylated for 14-3-3 to bind to a target protein. Phosphorylation of serine in –2 
position does not enable 14-3-3 binding (4).  14-3-3 binds to a variety of signaling and 
structural proteins, thus it may act as a scaffold to bring different target proteins into 
complexes facilitated by its ability to form saddle-shaped dimers via interaction between 
amino terminal parts of the two 14-3-3 molecules (2).  
WW domains are relatively small 35-40 amino acid modules that bind proline-
rich sequences PPXY or PPLP. Recently it became apparent that certain WW domains 
bind target proteins in a phosphorylation specific manner. WW domains of prolyl 
isomerase Pin1 and ubiquitin ligase Nedd4 have been shown to recognize pSer/Thr-Pro 
motifs on target proteins (5). Pin1 is a prolyl isomerase, a protein whose function is cis-
trans isomerization of peptidyl-prolyl bond.  Pin 1 differs from other prolyl isomerases as 
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it is able to catalyze isomerization of pSer/Thr-Pro bond while it is known that 
phosphorylation of Ser or Thr residue in Ser/Thr-Pro sequences reduces the rate of 
isomerization for other prolyl isomerases (6).  WW domain of Pin 1 binds mitotic 
phosphoproteins via interactions with p-Ser or p-Thr. This binding occurs in a 
phosphorylation dependent manner for Pin 1 does not initiate binding to mitotic targets if 
they were dephosphorylated. The crystal structure shows that the Pin 1 WW domain has a 
hydrophobic cluster formed by different strands of β sheets (6). Co-crystallization of the 
WW domain of Pin 1 with a phosphopeptide substrate show the structural basis for WW-
Phosphorylated target interactions (7). WW domain of ubiquitin ligase Nedd4 has also 
been shown to associate with target proteins via phosphothreonine or phosphoserine 
interactions, which are responsible for presentation of proteins for ubiquitination (5;6). 
Forkhead associated domains (FHA) are conserved 55-75 amino acid modules 
that were originally found in forkhead family transcription factors (8). They are present in 
both eucaryotes and prokaryotes. FHA domain contains three highly conserved stretches 
of amino acid separated by variable regions. Each conserved stretch contains invariable 
residues in the middle of it – a Gly for the first and third, His for the second position. The 
secondary structure of FHA has a β strand structure. The majority of FHA proteins 
known today are nuclear proteins that fall into three categories – transcription factors, 
DNA repair proteins or cell cycle proteins. Yeast FHA containing DNA repair protein 
Rad53p is the best studied. It has two FHA domains, FHA1 and FHA2, both of which 
bind to target proteins in a phosphorylation dependent manner, specifically recognizing 
phospho-threonine (9;10). The FHA1 domain binds phospho-threonine containing 
sequences within the consensus pTXXD, whereas FHA2 binds pTXXI (11;12). Other 
FHA containing proteins display different preferences for amino acid in the +3 position 
though it is clear that their binding to target proteins is phospho-threonine specific. Liao 
and co-workers have shown that the FHA2 domain of Rad53p can also bind 
phosphotyrosine containing targets (9). Their data suggest that FHA domains may be 
dual specificity binding modules.  
WD 40 motifs were originally discovered in the β subunit of heterotrimeric G 
proteins (13). Since then they have been found in various other proteins. WD 40 motifs 
represent regions of approximately forty amino acids. Their characteristic feature is that 
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they always terminate with Trp-Asp (WD).  WD-40 motifs are always arranged in 
tandem with sequence similarity among them. In the past few years a number of reports 
indicated that WD-40 motifs of F-box containing proteins bind their target proteins in a 
serine/threonine phosphorylation-dependent manner (5). F-box proteins are the ones 
responsible for recognizing phosphorylated substrates and linking them to E3 ubiquitin 
ligases. The biochemical data accumulated on F-box-protein interactions with their 
substrates suggests that it is WD-40 repeat regions of F-box proteins that mediate F-box 
protein binding to the substrate (14-17).  Unlike for 14-3-3, WW and FHA domains, for 
WD-40 domains no experiment has been performed to provide us with structural proof 
that WD-40 indeed binds substrates in phospho-serine/threonine dependent manner.  
 
II.  Indirect effects: Serine/threonine phosphorylation of another protein enables it 
to become a binding partner for an adaptor protein. 
2.1 14-3-3 
14-3-3 proteins are small acidic proteins with a molecular weight around 30kDa 
(18). The 14-3-3 proteins are cellular components of all cells types that have been 
examined, and they have been found in all vertebrates, invertebrates, plants, and fungi 
(19;19-21) (20;21).  The 14-3-3 family of proteins includes seven unique isoforms, 
named by Greek letters according to their elution order after reverse-phase high-
performance liquid chromatography:β/α, ζ/δ, η, γ, τ, σ and ε (18;18;22;23). 14-3-3 
proteins are highly conserved among each other and across different species although 
they do have   differences in some regions (23;23;24). All 14-3-3 proteins are able to 
dimerize, with the ability to form both homo- and heterodimers in vitro and in vivo 
(21;21;25). Dimerization occurs via hydrophobic interactions between highly conserved 
residues within amino-terminal parts of the molecules (18;18;22;23;23). Carboxy-termini 
of two molecules brought together by dimerization create a ligand binding amphipathic 
groove (4;4;26). Highly conserved residues form the inner surface of the binding groove, 
whereas variable residues create the outer surface. This groove may bind either two 
different molecules or bring together different regions of the same protein therefore 
serving as a scaffold or allosteric regulator (26;27). The variant residues of the outer 
 5
surface of the groove may provide specific binding surfaces for different proteins. 14-3-3 
proteins bind two well-defined structural motifs on target proteins. The first contains 
phosphoserine in the center with arginine, serine and proline in positions –3, –2, and +2, 
respectively. Another one is defined as short amino acid sequence containing 
phosphoserine in the center with arginine, aromatic residue, basic residue and proline at 
positions –4, -2, -1, +2 respectively (4;4;18;28;28). 14-3-3 dimers could bind to several 
phosphoserine-containing motifs on one protein or bring several target proteins together 
as a consequence of binding to conserved motifs found on different proteins. 14-3-3 
dimers also may act as molecular links   between proteins bound to the conserved groove 
and ones associated with variable outer surface, therefore performing a role of scaffolds 
that regulate specific protein-protein interactions (26).  14-3-3 proteins have over 60 in 
vivo binding partners (2). 14-3-3 proteins have been implicated in regulation of 
serine/threonine kinases such Raf and PKC (19;19;22;29;30;30). 14-3-3 proteins bind Raf 
and certain PKC isoforms directly and therefore serve to facilitate interactions between 
these signaling proteins (27). 14-3-3 brings Raf into proximity with Bcr as well (2). Raf 
is a key protein kinase in mitogen activated protein kinase cascade. Raf functions 
downstream of growth factor receptor and Src-family non-receptor tyrosine kinases, and 
Ras, and upstream of MAP kinase to transmit developmental and proliferative signals. 
14-3-3 associates with Raf in vivo regardless of Raf subcellular localization or activation 
status (18;19;31;32). Overexpression of 14-3-3 proteins has been shown to contribute to 
Raf activation, although it is clear that 14-3-3 proteins are unable to activate Raf by 
themselves (32;32). Some other reports stated that the nature of 14-3-3 influence on Raf-
1 is inhibitory (33;34;34). The data on Raf-14-3-3 interaction accumulated to date 
suggests the following model of Raf-14-3-3 interaction: Raf has three 14-3-3 binding 
sequences in its structure. 14-3-3 is bound to cytosolic Raf at amino-terminal and carboxy 
terminal binding sites; this association serves to keep Raf in an inactive, although 
activatable, state. Upon Raf activation by Ras the former undergoes translocation to the 
membrane. The 14-3-3 dimer is displaced from the amino terminal binding site on Raf, 
but it still associates with the carboxy terminal 14-3-3 binding site. Yet unidentified 
kinases come along and phosphorylate the serine in the center of the intermediate 14-3-3 
binding site of Raf and 14-3-3 binds to it, stabilizing Raf in an active state (4;4;30). 14-3-
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3 therefore has a dual role in Raf regulation, it keeps Raf in an inactive state in the 
cytosol, but upon Ras-dependent Raf activation it stabilizes it in an active conformation.  
14-3-3 proteins also have been shown to be both PKC substrates and regulatory proteins 
(35;36). 14-3-3 may bind to Raf and PKC at the same time, therefore bringing Raf to 
proximity with PKC to ensure phosphorylation of the former by the latter (18;18;27;37). 
14-3-3 binding to a target protein often serves to keep that protein either in 
inactive state and/ or sequester it from binding partners. 14-3-3 binds Cdc25C 
phosphatase in a phosphorylation dependent manner via its RSXpSXP site –the perfect 
consensus for 14-3-3 binding. This interaction is responsible for keeping this protein 
inactive throughout G1, S and G2 phases of the cell cycle and also transports it from the 
nucleus to cytosol (38;39). 14-3-3 bind the apoptotic protein BAD in a phosphorylation 
dependent fashion. The function of this interaction is to sequester BAD in the cytosol and 
keep it from binding to Bcl2 and also possibly protecting it from phosphatases (40). 14-3-
3 binds IRS-1 and therefore prevents its association with PI3K (41). 
Dubois and colleagues show that two unidentified brain kinases phosphorylate 14-
3-3 on the sites located at C terminus of 14-3-3, a region where PI3K, Raf and Cbl bind 
to 14-3-3 (42). Therefore, they speculate that phosphorylation regulates 14-3-3 
interactions with binding partners. They also refer to the data of Aitken and colleagues 
that leads to suggestion that 14-3-3 α and δ, which are phosphoisoforms of 14-3-3 β and 
ζ, respectively, may influence PKC activity more strongly than their non-phosphorylated 
counterparts(29).  Later that year they followed with another publication where they 
determined the identity of the brain kinase that phosphorylates Ser233 of 14-3-3 as casein 
kinase 1 (43). Another kinase that utilizes 14-3-3 as a substrate is sphingosine dependent 
protein kinase SDK1 (44). The function of 14-3-3 phosphorylation remains to be 
determined.  
2.2.  p130Cas. 
Crk associated substrate p130Cas was discovered over a decade ago as a 
phosphotyrosine-containing binding partner for active Src and Crk (45). The Cas domain 
structure along with variety of binding partners, suggests that it acts as an adaptor protein. 
The domain structure from amino to carboxy terminus: SH3 domain, proline rich region, 
 7
so-called “substrate-binding”  domain that associates with adaptor proteins Crk, Nck and 
SHIP, serine rich motif and a carboxy-terminal region that interacts with different protein 
kinases and adaptor proteins (45). Cas is involved in regulation of cell motility, 
cytoskeleton integrity, growth regulation, apoptosis, and Src and Crk dependent 
transformation (45). Cas is localized to focal adhesions where it associates with Crk, Src 
and FAK. FAK/Cas interaction occurs via proline-rich region of FAK and SH3 domain of 
Cas (46;47). Cas forms a complex with Crk at focal adhesions; Cas/Crk complexes 
influence cytoskeletal rearrangements in a Rac1-dependent manner (45;48).Focal 
adhesions are the sites where actin stress fibers are linked to extracellular matrix. Focal 
adhesions are also the sites of integrin signaling (49). 
The data accumulated so far suggests that Cas is involved in the regulation of 
cytoskeletal integrity, cell-matrix adhesion and cell motility. In Cas knockout cells actin 
filaments are disorganized but formation of focal adhesions remains intact (50).  
Cas, as well as FAK and paxillin, is phosphorylated on serine/threonine residues 
in mitosis and concomitantly dephosphorylated on tyrosine residues (49). Mitosis is the 
stage of the cell cycle when cells display actin filament disorganization and detachment 
from the substratum. Mitotic phosphorylation of focal adhesion proteins must be a way of 
cell detachment regulation. Serine phosphorylation of Cas and FAK during mitosis 
promotes their dissociation from one another. Mitotic FAK is able to reassociate with 
interphase Cas following ser/thr phosphatase treatment, therefore FAK/Cas interaction 
does not depend on tyrosine phosphorylation of FAK as ser/thr dephosphorylated mitotic 
FAK has no tyrosine phosphorylation. These data indicate that serine/threonine 
phosphorylation of FAK and not its tyrosine phosphorylation regulates FAK/Cas 
complex formation (49).  Ma and co-workes confirm that serine/threonine 
phosphorylation of FAK down-regulates its ability to form a complex with Cas (51). The 
physiological significance of serine/threonine phosphorylation of Cas itself remains to be 
determined. 
2.3.  AP-2 
Adaptor protein 2 is a multisubunit adaptor protein complex associated with 
endocytic clathrin coated vesicles. AP2 associates with proteins like EGF receptor 
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substrate Eps15 and Epsin at the membrane. This association is disrupted in mitosis when 
both Eps15 and Epsin are phosphorylated on ser/thr residues. Eps15 and Epsin are 
substrates for p34Cdc2 in vitro. Ser/thr phosphorylation of epsin and Eps15 results in 
dissociation of these proteins from AP2 complex. This may provide a mechanism that 
inhibits clathrin-mediated endocytosis in the stage of mitosis (52;53). 
 
III.  Adaptor proteins that are serine/threonine phosphorylated but function of 
phosphorylation remains to be determined. 
3.1.  Chat. 
Chat is a Cas/HEF-1 associated adaptor protein isolated by Sakakibara and 
Hattori last year (54). The function of Chat itself as well as the function of its 
phosphorylation has not been determined. Sakakibara and Hattori show that Chat binds 
the adaptor protein Cas directly, and this interaction is phosphorylation-independent (in 
vitro binding assay). Chat has multiple serine/threonine residues, four of which comprise 
potential MAPK sites (PXS/TP). Phosphorylation levels of Chat increase in response to 
growth factor treatment, and it is not due to tyrosine phosphorylation (there is a gel shift 
in response to GF treatment, but pTyr Ab does not react with the upper portion). MAP 
kinase may be the one responsible for GF mediated phosphorylation of Chat as MAPK 
inhibition results in the disappearance of the slower migrating band. Overexpression, but 
not phosphorylation, of Chat up-regulates JNK activity in a manner similar to that of Cas. 
Chat is a cytoplasmic protein, but in response to GF stimulation it moves to membrane 
ruffles where it colocalizes with actin (54).  
3.2.  NHERF. 
NHERF is a Na+/K+ exchange regulatory factor that was discovered several years 
ago and since then it became apparent that this is an adaptor protein. NHERF contains 
two PDZ domains in tandem where the majority of NHERF binding partners associate, 
along with the carboxy-terminal region that binds ERM proteins.  NHERF proteins are 
localized to the plasma membrane, where in addition to already mentioned function as 
Na+/K+ exchange regulators they also regulate transmembrane receptors and are 
involved into growth factor receptor signaling (55).   
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In 1995 Weinman and colleagues suggested that NHERF may be a substrate for 
serine/threonine phosphorylation for they found potential sites for PKA phosphorylation 
in the C-terninus of NHERF (56). A more recent report by Hall and co-workers shows 
that NHERF is constitutively phosphorylated on serine/threonine residues, and that 
NHERF is a binding partner and an in vitro substrate for a G protein receptor coupled 
kinase GRK6A (57).  The functional significance of NHERF phosphorylation remains to 
be determined.  
NHERF proteins are able to dimerize. The physiological significance of this 
capability still remains to be determined. The ability of NHERF proteins to dimerize is 
greatly diminished in response to okadaic acid treatment. It seems therefore that protein 
phosphorylation might be responsible for regulation of the ability of NHERF proteins to 
self-associate, although it is not known at this point whether phosphorylation of NHERF 
themselves or NHERF binding partners influenced this effect (58). 
3.3.  Nck/Dock 
Nck is an adaptor protein that was discovered in 1990 (59). Its domain structure 
suggests that it serves as an adaptor protein. Nck has three SH3 domains in tandem 
followed by an SH2 domain at the carboxy-terminus. Indeed, it binds a variety of target 
proteins such as protein kinases, adaptor and motor proteins, involved in regulation of 
actin filaments integrity, DNA synthesis, transcription and translation as well as protein 
degradation (reviewed in (60).  
Two reports published in 1992 show that Nck is phosphorylated in growing cells 
and in response to PMA or growth factor stimulation of cultured cells (61;62). 
Phosphoamino acid analysis has demonstrated that Nck is phosphorylated predominantly 
on serine/threonine with one tyrosine phosphorylated peptide recovered. Neither the 
identity of serine/threonine kinase nor the physiological role of serine/threonine 
phosphorylation of Nck was determined (61;62). 
3.4.  Grb7. 
Grb7 is a 535 amino acid protein with similarity to Grb2, Shc and Nck. Grb7 
family includes Grb7, Grb10 and Grb14 proteins. Grb7 proteins contain several protein-
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protein interaction modules such as proline-rich, PH, Ras-associating, and SH2 in their 
structure, which enable them to interact with a variety of signaling proteins and therefore 
serve as adaptors linking receptor activation to downstream signaling pathways (63). 
Grb7 is able to form homo- or heterodimers and larger complexes (64).  Dimerization of 
the Grb7 family of proteins may serve to bring signaling proteins together into large 
complexes. Grb7 family of adaptors has been implicated in the regulation of cell 
proliferation, cell motility, apoptosis and tumorigenesis (63). 
The Grb7 family of adaptor proteins is constitutively phosphorylated on 
serine/threonine residues, and the level of their serine/threonine phosphorylation 
increases in response to EGFR and heregulin receptor stimulation (65-67)). The 
functional significance of this phosphorylation remains to be determined.   
 
IV.  Direct effects: Serine/threonine phosphorylation of an adaptor protein recruits 
in a binding partner for it. 
4.1.  Paxillin. 
Paxillin was initially discovered as a tyrosine phosphorylated protein from Src 
transformed cells (68). Paxillin is localized to focal adhesions, where it serves as a 
scaffold for a wide variety of signaling and structural proteins. The ability of paxillin to 
bind various proteins is attributed to several protein-protein interaction domains  - i.e., 
LD motifs and SH2 and SH3 binding motifs in the amino terminus and four LIM 
domains in the carboxy terminus. LD motifs are conserved eight amino acid leucine rich 
sequences (LDXLLXXL), serving as binding sites for a number of paxillin binding 
partners such as FAK, vinculin, and PYK2. LIM domains are double zinc finger motifs 
approximately 50 amino acids long whose function is to serve as protein-protein binding 
modules. LIM domains of paxillin promote its localization to the plasma membrane via 
association with integrins. Paxillin is crucial for embryogenesis since paxillin knockout 
mice die on the seventh-eighth day of embryogenesis (69). Paxillin deficient cells display 
an inability to spread (70). 
Tyrosine phosphorylation of paxillin and its functional significance has been 
extensively studied for some time, while serine/threonine phosphorylation has started to 
draw attention only recently. Paxillin is phosphorylated on serine residues in vivo in 
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response to plating of cultured cells on vitronectin or fibronectin, and also in mitosis and 
in MCF-7 cells in response to heregulin stimulation (49;71-73). The identity of 
serine/threonine kinases that phosphorylate paxillin in vivo is unknown although it is 
known that paxillin is serine phosphorylated in response to PKC activation following 
PMA treatment and treatment with a PKC inhibitor reduces paxillin serine 
phosphorylation (71). The fact that paxillin is phosphorylated upon adhesion of cells to 
ECM was confirmed by (74). Their work is cell type specific for EL4 cells, which 
represent murine thymoma cell line. These cells display an ability to adhere in response 
to PMA treatment. PMA treatment also results in serine phosphorylation of paxillin. The 
signaling cascade may proceed from PMA stimulation via MEK/ERK pathway to 
adhesion. If a specific inhibitor of MEK activation is added, there is a reduction in a 
number of adherent cells. ERK is one (though not only) kinase that is activated 
downstream of PKC in these cells. MEK/ERK inhibitor abolished PMA induced paxillin 
phosphorylation leading to the suggestion that the proceeds from PKC via MEK/ERK 
pathway to paxillin.  Paxillin is a substrate for ERK2 in vitro (74). Recent data of 
Hashimoto and co-workers indicate that paxillin associates with PAK3 and serves as a 
substrate for this kinase in vitro (75). 
Paxillin has four LIM domains in its carboxy terminus. GST-LIM2 and GST-
LIM3 constructs were phosphorylated on threonine or serine, respectively, in vitro 
(whereas GST-LIM1 and GST-LIM4 were not). Site directed mutagenesis was employed 
to identify phosphorylation sites within LIM2 and LIM3 domains.  LIM3 and LIM2 
become phosphorylated during cell adhesion to fibronectin in vivo. Phosphorylations of 
LIM domains of paxilllin promote localization of this protein to focal adhesions. Certain 
site-directed mutants of paxillin, which have serine or threonine mutated to alanine or 
valine, respectively, do not localize to focal adhesions as efficienltly as a wild type, and 
as a result these cells adhere to fibronectin poorly. Serine/threonine phosphorylations of 
LIM domains bring paxillin to newly created focal adhesions (76).  
Serine/threonine phosphorylation of paxillin also has a role in cell movement, 
which was described in a paper by Vadlamudi and colleagues (73). They found that 
MCF-7 cells invasiveness is increased in response to heregulin exposure. Along with this, 
in response to heregulin treatment paxillin becomes phosphorylated on serine and 
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threonine residues (73) as demonstrated by SDS-PAGE mobility shift, phosphoamino 
acid analysis and serine/threonine phosphatase versus tyrosine phosphatase treatments; 
the latter does not interfere with heregulin induced phosphorylation of paxillin (73). This 
group of researchers found that two pools of paxillin are present in MCF-7 cells: one of 
them is co-localized with focal adhesions, while the other is cytoplasmic. Heregulin 
treatment causes relocation of paxillin from focal adhesions to perinuclear areas of the 
cytoplasm accompanied by changes in cell shape. Serine/threonine phosphorylation of 
paxillin and accompanying cell scattering are dependent upon p38MAPK rather than 
p42/44MAPK pathway activation, which has been demonstrated by use of specific MEK 
inhibitors. Overall, these data indicate that heregulin treatment leads to paxillin relocation 
from focal adhesions, that promotes their disassembly, which is necessary for cell 
movement to occur (73). 
4.2.  Gab1. 
The name Gab1 stands for Grb2 associated binder 1. In response to insulin, 
cytokine or growth factor stimulation (HGF, EGF, NGF, PDGF) Gab1 becomes 
phosphorylated on tyrosine and binds the tyrosine-phosphorylated receptor directly, or 
indirectly via Grb2 in a phosphorylation dependent manner (77). Gab1 has an amino 
terminal PH domain that tethers Gab1 at the membrane via PIP3 interaction and carboxy 
terminal Met binding domain (MBD) that mediates direct interaction of Gab1 with cMet, 
and also has binding sites via which it interacts with SH3 domain of Grb2. There are 21 
tyrosine residues in between these two regions, which upon phosphorylation serve as 
docking sites for a number of binding partners.  The list of Gab1 binding partners 
includes Grb2, cMet, p85 subunit of PI3K, PLCγ, Shc, Shp2 phosphatase, Crk and CrkL 
(77-79).   
Phosphoaminoacid analysis of Gab1 overexpressed with dominant negative or 
positive MEK shows that serine/threonine phosphorylation levels of Gab1 are elevated in 
response to co-expression with constantly active MEK. Gab1 binds phosphorylated 
ERK2 directly and phosphorylated by it; Gab1 also associates with phospho-Erk1 in 
response to MEK activation (80). Several years later this same group of authors followed 
with another report, which demonstrates that cMet activation results in MAPK cascade 
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activation, and Gab1 becomes phosphorylated by active ERK2 followed by recruitment 
of PI3K to the membrane (78). Consequently, Akt activation follows in response to PI3K 
activation as a result of an association with Gab1. They state that Gab1 has to be 
phosphorylated both on threonine and tyrosine residues to ensure for PI3K association 
(78).  
Okadaic acid treatment of cultured cells results in serine/threonine 
phosphorylation of Gab1 (81). One of the effects of cMet stimulation by HGF is cell 
scattering, which is the result of c-Met stimulated increased cell motility. Okadaic acid 
treatment of cultured cells prior to HGF stimulation prevents cell scattering. Under these 
conditions Gab1 is found to be hyper-phosphorylated on serine and threonine residues 
and hypo-phosphorylayed on tyrosine residues. Okadaic acid promoted decrease in 
tyrosine phosphorylation of Gab1 is a consequence of its elevated serine/threonine 
phosphorylation which by some undetermined mechanism prevents cMet form 
interacting with and phosphorylating Gab1 (81) .  
Serine/threonine phosphorylation results in   Gab1 association with 14-3-3. The 
functional significance of this interaction remains to be determined, as it does not seem to 
interfere with Gab1/Met1 interactions and therefore sequester Gab1 from the membrane.  
Okadaic acid activates MAPK and PKC by inhibition of serine/threonine phosphatases. 
Using pharmacological agents that are known to be specific inhibitors of MAPK pathway 
or PKC kinase, they show that for serine/threonine phosphorylation of Gab1 in response 
to okadaic acid treatment is PKC dependent.  Phorbol ester treatment results in a decrease 
of both electrophoretic mobility and tyrosine phosphorylation levels of Gab1. Gab1 is a 
substrate for conventional PKC isozymes in vitro. PKC inhibitor staurosporine treatment 
restores cell scattering inhibited by okadaic acid (81).  The authors hypothesize that 
serine/threonine phosphorylation alters Gab1 conformation so that tyrosine residues 
cannot be presented for phosphorylation; as a consequence, the docking sites for binding 
partners are not being created which results in Gab1 inability to associate with them (81) .  
4.3. PECAM-1. 
Platelet endothelial cell adhesion molecule 1 (PECAM-1) is a transmembrane 
glycoprotein belonging to immunoglobulin family of adhesion molecules that is 
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expressed only in hematopoetic and vascular cells. Upon phosphorylation of tyrosines 
within its ITAM motif it becomes a binding partner for PI3K, PLCγ, SHP1 and 2, Stat5a, 
and cell-cell junction proteins catenins β and γ (82-84). PECAM-1 is phosphorylated not 
only on tyrosine but also on serine and threonine residues. The levels of serine/threonine 
phosphorylation of PECAM-1 are elevated in response to LPS treatment of monocytes in 
a PKC dependent manner, which is demonstrated by the observation that PKC inhibitor 
treatment downregulates LPS induced serine/threonine phosphorylation of PECAM-1 
(85). Along with PECAM-1 serine/threonine phosphorylation LPS induces 
transendothelial migration of monocytes.  Phosphorylation of PECAM-1 on serine and 
threonine residues appears to be connected to cell migration, this conclusion comes from 
the fact that PKC inhibitor treatment blocks monocyte migration through the endothelial 
cell layer (85). Phosphatase inhibitor treatment up-regulates both PECAM-1 
serine/threonine phosphorylation and transendothelial movement of monocytes. These 
data suggests that PECAM-1 may be involved in the regulation of monocytes movement 
(85). 
PECAM-1 is able to associate with both β and γ catenins (82). Serine/threonine 
phosphorylation of PECAM-1 has been shown to down regulate its ability to associate 
with γ catenin (83). PECAM1 is a substrate for PKC in vitro and phosphorylated on 
serine/threonine residues in response to PKC activation in vivo (83). In response to PKC 
activation by DAG a decrease in PECAM-1 interaction with γ catenin is observed, 
whereas PKC inhibitor bisindolylmaleimide treatment promotes this interaction. PKC, 
therefore, may be the kinase responsible for serine/threonoine phosphorylation of 
PECAM-1 in vivo and PKC dependent serine/threonine phosphorylation of PECAM-1 
may be a mechanism of regultion PECAM-1/γ catenin interactions. Experiments of Ilan 
and colleagues suggest that one of the functions of PECAM-1 may be to bring catenins to 
adherence junctions (83); PECAM-1 interaction with γ catenin is thought to link 
PECAM-1 to the cytoskeleton via vimentin and therefore participate in transduction of 
signals that regulate cell migration (83).  
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4.4.  Sos. 
In response to growth factor stimulation receptor tyrosine kinases will 
autophosphorylate on tyrosine residues, creating binding sites for the adaptor proteins 
Grb2 and Shc. They, in turn, recruit a protein named Son of sevenless (Sos) to the 
membrane. Sos protein is a guanine nucleotide exchange factor for Ras. Once at the 
membrane, Sos promotes GDP to GTP exchange on Ras, activating it. Sos links growth 
factor receptor activation to Ras stimulation (86). It was determined several years ago 
that Sos1 is phosphorylated in response to EGFR stimulation (87). Phospho amino acid 
analysis determined that Sos is phosphorylated predominantly on serine and to the lesser 
extent on threonine residues, while no tyrosine phosphorylation was detected (88). It was 
observed that the C terminus of Sos contains potential sites for MAPK phosphorylation. 
Indeed, using phosphotryptic-mapping analysis it was demonstrated that Sos is a 
substrate for MAP kinase both in vitro and in vivo, and the sites of phosphorylation were 
identified (89;90). Since it has been determined that Sos protein is serine/threonine 
phosphorylated, researchers have been trying to elucidate the functional significance of 
Sos phosphorylation. Rozakis-Adcock and co-workers demonstrated that serine/threonine 
phosphorylation of Sos downregulates Sos-Grb2 association with EGFR and Shc 
although does not affect Sos interaction with GST-fused Grb2 (88). Corbalan-Garcia and 
colleagues discovered that in response to being phosphorylated Sos dissociates from 
Grb2.    The data accumulated by the two groups must be somewhat controversial, which 
might be explained by the differences in exprerimental setup and also by the fact that 
these groups of authors used Sos from different species (either human or murine) in their 
experiments. Both groups agree that MAPK dependent Sos phosphorylation serves as a 
feedback mechanism of Ras/MAPK pathway regulation. Sos is phosphorylated in MAPK 
cascade dependent manner by active MAP kinase and supposedly by other 
serine/threonine kinases that are activated downstream of MAPK pathway (88;89).  
In T cells the MAPK cascade is activated in response to TCR ligation. Both TCR 
activation and PMA stimulation result in serine/threonine phosphorylation of Sos-1; this 
is demonstrated by reduced mobility of Sos-1 derived from PMA stimulated cells (91). 
The mobility shift is lost if phosphatase treatment has been applied to Sos-1 from PMA 
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treated cells. In T cells serine/threonine phosphorylation of Sos-1 is not MAPK cascade 
dependent, this conclusion comes from the observation that MEK inhibitor treatment 
does not result in decrease in serine/threonine phosphorylation levels of Sos-1 promoted 
by TCR engagement. Mutation of seven potential MAPK consensus sites does not 
diminish ability of Sos-1 to be phosphorylated on serine/threonine residues either (91).  
It is well known that prolonged exposure to PMA results in depletion of cellular 
pool of PKC due to its subsequent ubiquitination (92;93). When cells that had undergone 
16-hour PMA treatment were subjected to TCR stimulation no serine/threonine 
phosphorylation of Sos was detected. The same result was observed in cultured cells pre-
treated with specific PKC inhibitors (91). Therefore, PKC may be a Sos kinase in vivo. 
Phosphorylation of Sos did not lead to its uncoupling from Grb2 under described 
conditions, which is in agreement with previous data of Rozakis-Acock and co-workers. 
Zhao and colleagues did not attempt to clarify the functional significance of Sos 
phosphorylation (91).  
4.5.  Cbl. 
c-Cbl is an adaptor protein that is ubiquitously expressed and known to be 
phosphorylated on tyrosine residues (94). Cbl has several modular domains including a 
zinc ring finger motif, SH2 and SH3 binding motifs and leucine zipper motif. These 
modules facilitate the association of Cbl with 40 target proteins, among which are 
receptor and non-receptor tyrosine kinases, E2 ubiquitination enzyme, p85 subunit of PI3 
kinase, and adaptor proteins such as Crb2, Nck, and Crk. Cbl has the ability to form 
dimers via its carboxy-terminal leucine zipper motif.  T cell receptor activation leads to 
tyrosine phosphorylation of Cbl and its transient association with CrkL and the p85 
subunit of PI3K (94;95). P85 binds Cbl directly but it cannot bind CrkL, unless it 
associated with Cbl that brings it into a close proximity with CrkL.  Cbl has to be tyrosine 
phosphorylated to perform this function. Cbl, therefore, act as a scaffold that brings PI3K 
and CrkL together (95).  
Liu and co-workers found that TCR ligation leads to serine/threonine 
phosphorylation of Cbl upon which Cbl becomes associated with 14-3-3 (96). Cbl 
interaction with 14-3-3 is direct and occurs only in response to TCR (96) or CD43 (97) 
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ligation; while in unstimulated cells there is no Cbl-14-3-3 complex detected. 14-3-3 
displaces PI3K from Cbl. Serine/threonine phosphorylation of Cbl has also been shown 
to downregulate its tyrosine phosphorylation and association with another partner, the 
adaptor protein CrkL (96). PMA treatment promotes serine/threonine phosphorylation of 
Cbl and its consequent association with 14-3-3. Pretreatment of cells with specific PKC 
inhibitors prior to PMA treatment results in an inability of PMA to induce 
serine/threonine phosphorylation of Cbl. Cumulatively, these data suggest that Cbl 
phosphorylation may be PKC dependent (95;97;98). PMA treatment also results in a 
decrease in tyrosine phosphorylation levels of Cbl and therefore promotes its dissociation 
from p85 and CrkL.  Recent work of Pedraza-Alva and co-workers shows that CD43 
receptor cross-linking causes Cbl association with Vav and PI3K; the latter is activated in 
response to this interaction event (97). It is noteworthy that Cbl does not have to be 
phosphorylated on tyrosine residues for described CD43 induced interactions to occur, as 
there is no tyrosine phosphorylation of Cbl detectable under those conditions.  Pedraza-
Alva and colleagues attempted to gain an insight into the functional significance of 
serine/threonine phosphorylation of Cbl (97). It has been known for some time that 
overexpression of Cbl has an inhibitory effect on receptor-mediated MAP kinase 
activation. PKC dependent phosphorylation of Cbl followed by its association with 14-3-
3 is thought to block the negative effect of Cbl on MAP kinase cascade activation (97). 
Serine/threonine phosphorylation of Cbl also negatively regulates Cbl tyrosine 
phosphorylation and therefore hampers its interaction with PI3K, CrkL and other 
phosphotyrosine binding partners. All the data on Cbl serine/threonine phosphorylation is 
T cell specific. Cumulatively, it leads to the conclusion that adaptor protein Cbl is 
phosphorylated on tyrosine and serine/threonine via two separate receptor-signaling 
pathways. Phosphorylation on either tyrosine or serine/threonine residues may enable Cbl 
to associate with different set of binding partners and therefore be engaged in either one 
of the two signaling cascades descending from the T cell receptor. 
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4.6.  IRS1. 
Insulin receptor substrate 1 is a 165-185 kDa protein that associates with SH2 
containing proteins in a phosphorylation dependent manner.   IRS1 becomes 
phosphorylated on tyrosine residues by insulin receptor and consequently associates with 
PI3 kinase, activating the latter. PI3 kinase activation results in activation of Akt/PKB, 
which sends the signal further downstream.  The physiological consequences of insulin 
receptor signaling are glucose uptake and glycogen synthesis. In response to PDGF (in a 
PI3K/Akt dependent manner) (99;100) or endothelin-1 (in a PKC and MAPK dependent 
manner) (100) stimulation IRS1 becomes phosphorylated on serine residues, four of 
which are MAPK consensus sites (101).  Serine phosphorylation of IRS1 leads to the 
decrease in its tyrosine phosphorylation levels (99;100) and IRS1/PI3K complex 
disengagement (100;102) therefore inhibiting insulin receptor signaling. PDGR receptor 
stimulation results in inhibition of insulin receptor signaling, cased by inability of IRS-1 
to be tyrosine phosphorylated and form a complex with PI3K. The IRS1 mutant, which 
has four serine residues substituted by alanines, retains the ability to be tyrosine 
phosphorylated in response to insulin treatment in the presence of PDGFR stimulation 
and associate with PI3K, activating it. In response to Akt activation IRS1 association 
with PI3K is abrogated. It is not known yet whether Akt phosphorylates IRS-1 directly or 
simply promotes IRS-1 phosphorylation by activating serine/threonine kinase(s) 
downstream of it (100). Whatever the mechanism might be, attenuation of insulin-
receptor signaling by active Akt suggests a model for negative feedback loop where PI3 
kinase, activated in response to insulin-receptor stimulation via IRS-1 interaction, in turn 
activates Akt, which comes along and phosphorylates IRS-1 causing dissociation of IRS-
1/PI3K complex (100). 
Ogihara and colleagues (103) and Staubs and co-workers (99) observe 
serine/threonine phosphorylation of IRS1 in response to PI3K association promoted by 
insulin receptor activation.   IRS1 is a substrate for PI3K in vitro (104;105). These data 
suggests that PI3 kinase itself may be responsible for an attenuation of insulin receptor 
signaling.  Ogihara and co-workers also suggest that serine phosphorylation of IRS1 may 
lead to presentation of phospho tyrosines for tyrosine phosphatases therefore enabling 
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attenuation of insulin signaling (103).  
Decrease in tyrosine phosphorylation of IRS1 was also observed in response to 
PMA treatment of cultured cells (106). Activation of endogenous PKC by phorbol ester 
treatment inhibits insulin receptor-mediated tyrosine phosphorylation of IRS-1.  It has not 
been demonstrated whether IRS1 is a substrate for PKC either in vitro or in vivo (106).  
PKC is known to activate ERK1/2 in response to its activation. IRS1 is a substrate 
for ERK1/2 in vitro (107). IRS1 contains four potential MAPK sites of a consensus 
PXS/TP. PKC activates ERK1/2 in Raf-1 dependent manner. Both ERK1/2 and Raf 
activation result in decreased insulin receptor mediated tyrosine phosphorylation of IRS1 
in vivo, resulting in diminished IRS1/PI3K association (107).  
Both insulin and PDGF receptor activation lead to PI3 kinase activation by 
different mechanisms, which are responsible for different outcomes. IRS-1 is a key player 
in insulin receptor signaling as it activates PI3K via association with it and thereby 
triggers insulin-receptor mediated physiological events. PDGF receptor activates PI3 
kinase via another pathway and causes PI3K dependent serine/threonine phosphorylation 
of IRS-1, interfering with insulin receptor signaling. Serine/threonine phosphorylation of 
IRS-1 was observed in response to activation of insulin receptor, which is in agreement 
with the statement that serine/threonine phosphorylation of IRS-1 may provide the means 
for a negative feedback regulation of insulin receptor signaling. 
4.7.  pShc66. 
Shc is a ubiquitously expressed adaptor protein, which plays an important role in 
growth factor receptor signaling. Upon tyrosine phosphorylation by ligand-activated 
receptor tyrosine kinases Shc becomes a docking molecule for Grb2 allowing Grb2 to 
bring Ras-GTP Sos to the membrane. Three isoforms of Shc are known – two of them, 
p46 Shc and p52 Shc are synthesized from the same transcript  (starting sites differ), 
whereas p66 Shc is a result of alternative splicing (108;109). The three members of Shc 
family may have different biological functions (109;110). p66 Shc, for example, plays a 
role in regulation of oxidative stress response and life span in mice (111). Shc66 
knockout mice have a prolonged life span and increased resistance to oxidative stress 
(111). p46 Shc and p52 Shc cannot substitute for the p66 defect in p66Shc  deficient 
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mice. Oxidative stress response mediated by p66 Shc is serine phosphorylation 
dependent, which is demonstrated by the fact that non-phosphorylated p66Shc cannot 
revert mice to a normal phenotype (111). EGFR stimulation results in both tyrosine and 
serine/threonine phosphorylation of the p66Shc isoform in CHO cells, which is 
demonstrated by a mobility shift characteristic of serine/threonine phosphorylation. 
Moreover, p66Shc has to be phosphorylated on tyrosine prior to serine/threonine 
phosphorylation. Serine/threonine phosphorylation of p66Shc is /MAPK cascade 
dependent, although the identity of the kinase is unknown. Upon serine/threonine 
phosphorylation the ability of p66Shc to bind EGFR is abolished, although it is still able 
to associate with Grb2. p66Shc competes with p52Shc for Grb2 as the amount of Grb2 in 
cells is limiting. Therefore, in response to serine/threonine phosphorylation p66Shc 
carries Grb2 away from the EGFR. Overexpression of p66 Shc inhibits ERK activation 
(112). These data suggest the existence of a negative feedback regulation of EGFR 
signaling. EGFR ligation leads to engagement of Shc/Grb2/Sos complex via which 
activation of Ras/Raf/ MEK/ERK cascade occurs.    Serine/threonine phosphorylation of 
p66Shc leads to disengagement of Shc/Grb2 complex from the EGFR leading to 
attenuation of the EGFR signaling (112).   In mesangial cells p66Shc is serine/threonine 
phosphorylated in response to endothelin-1 receptor stimulation (113). p66Shc 
serine/threonine phosphorylation occurs in response to ERK1/2 activation although the 
identity of kinase that phosphorylates Shc66 under these conditions is unknown. Serine 
phosphorylation of p66Shc brings it into proximity with three proteins two of which 
remain to be identified and the third is 14-3-3 (113). Function of p66Shc association with 
14-3-3 remains unknown.  As 14-3-3 is known to bind a wide variety of proteins, and the 
14-3-3 dimer is capable of binding two different proteins at once, it may either bring 
p66Shc into proximity with some yet unidentified binding partner(s) for undetermined 
purpose or simply to sequester p66Shc from the membrane, preventing it from competing 
with two other Shc isoforms for Grb2 pool.  
Taxol, an antitumor agent that has already been approved for treatment of breast, 
lung, and ovarian carcinomas, causes serine/threonine, but not tyrosine, phosphorylation 
of pShc66 in human lung carcinoma cells (114). Serine/threonine phosphorylated p66Shc 
prevents it from interacting with Grb2. Although phosphorylation of Raf-1 and ERK1/2 
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is observed simultaneously with p66Shc phosphorylation, these kinases are not 
responsible for serine/threonine phosphorylation of pShc66. Taxol-mediated serine 
phosphorylation of p66Shc is protein synthesis dependent, as cycloheximide treatment 
inhibits taxol-induced phosphorylation of p66Shc and Raf-1. These data lead to 
hypothesis that taxol-inducible p66Shc activation occurs in response to stimulation of yet 
unknown signaling pathway, different from the MAP kinase cascade (114).   
Taxol is a microtubule-interacting agent that is capable of arresting cell in mitosis 
and it also has an apoptotic effect. As the serine/threonine phosphorylation of Shc reaches 
maximum at 9-18 hours after treatment, when cell may be in the mitotic stage, the 
authors speculate that Shc66 ser/thr phosphorylation may be responsible for transducing 
an apoptotic signal (114) referring to the fact that Ser→Ala substitution of p66 Shc 
enhances resistance to apoptosis (111).  
 
V. Direct effects: Serine/threonine phosphorylation of an adaptor protein alters its 
conformation and subsequent function. 
5.1. Cortactin. 
Cortactin was initially identified as a tyrosine phosphorylated substrate of active 
Src (115). Cortactin has an amino terminal acidic (NTA) domain followed by a region of 
cortactin repeats; alpha-helical domain, proline rich motif containing tyrosines, serine and 
threonine residues in abundance and a carboxy-terminal SH3 domain (116). Cortactin is 
localized to cortical actin structures. Recently it has been found that cortactin is involved 
in regulating cell motility (117). Cortactin’s structure along with its localization and 
ability to bind actin, suggests that this protein may be positioned to link signaling events 
such as growth factor receptor activation to actin filament reorganization(118). Cortactin 
is found to be phosphorylated in response to growth factor receptor stimuli. 
Phosphorylation therefore may play a role in regulation of its function (116).  
Van Damme and co-workers in 1997 have shown that in response to EGF 
receptor stimulation of cortactin over expressing human squamous carcinoma cell line 
p80 cortactin is converted into p85 cortactin and this conversion is a result of 
phosphorylation (119).  Phosphoamino acid analysis has shown that EGF-induced 
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cortactin phosphorylation occurs predominantly on serine and threonine residues. 
Immunofluorescence analysis indicated that upon growth factor induced phosphorylation 
cortactin relocates from perinuclear space to cell-matrix adhesion zone.  
Campbell and colleagues show that endogenous p80 cortactin is converted into 
the p85 form in response to EGF stimulation, confirming van Damme and co-workers 
data. They also show that cortactin phosphorylation is ERK dependent since pre-
treatment with the specific MEK inhibitor PD98059 abolishes EGF-induced cortactin 
phosphorylation. Active MEK is sufficient to cause cortactin phosphorylation but 
insufficient to prevent basal phosphorylation of cortactin which suggests that there are 
ser/thr kinases other than MAPK that phosphorylate cortactin in vivo. Proline-rich region 
have been shown to contain phosphate acceptor sites as it can be phosphorylated by Erks 
when expressed on its own (120).  Although the role of serine/threonine phosphorylation 
of cortactin still remains to be determined, from data described above it is possible that 
phosphorylation of cortactin may regulate its subcellular localization. Campbell and co-
workers speculate that the proline-rich domain of cortactin may interact with its own SH3 
domain and therefore keep cortactin in a “closed”  conformation. Serine/threonine 
phosphorylation of a proline-rich domain will result in abrogation of this interaction 
resulting in cortactin transition into the “open” conformation (120). Alternatively, ser/thr 
phosphorylation of the proline rich region of cortactin may disrupt its interaction with 
SH3 binding partners. The physiological significance of cortactin serine/threonine 
phosphorylation as well as its impact on conformation remains to be determined. 
5.2.  AFAP-110. 
AFAP-110 was first identified as a 110-kDa protein that co-immunoprecipitated 
with active Src in Src-transformed cells (121). In normal cells AFAP-110 co-localizes 
with actin stress fibers and the cortical actin matrix, frequently identified along the 
leading edge of the cell. AFAP-110 has several protein-protein interaction modular 
domains such as WW domain, SH2 and SH3 binding motifs, serine threonine kinase 
interaction domain, pleckstrin homology (PH) domains, leucine zipper motif, and 
carboxy terminal actin binding domains (122). AFAP-110 binds actin filaments directly 
via its carboxy-terminal actin binding sequences, and it associates with Src via SH2/SH3 
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interactions. The amino-terminal PH domain of AFAP-110 has been shown to facilitate 
its interactions with PKC (Qian et al, manuscript in preparation). AFAP-110 therefore 
may serve as an adaptor protein linking Src and PKC kinase activation to actin 
cytoskeleton reorganization. 
AFAP-110 has the capability to self-associate via interactions enabled by its 
carboxy-terminal leucine zipper motif. In non-transformed cells it exists in multiple 
forms including monomers, dimers, trimers, tetramers and even larger complexes. Upon 
co expression with active Src (Scr527F), AFAP-110 is detected as dimers, but not in larger 
complexes. Moreover, AFAP-110 self-association mode is altered in response to co-
expression with active Src. Normally, GST-tagged c-terminus of AFAP-110 is able to 
affinity absorb AFAP-110 from cell lysates; in response to co-expression with active Src 
this ability is diminished almost completely.  These data indicate that active Src causes a 
conformational change in AFAP-110 responsible for alteration in leucine zipper motif 
mediated self-association (123). It is also known that this alteration in AFAP-110 self-
association occurs is a result of serine/threonine phosphorylation, as AFAP-1105Y mutant 
which has five tyrosine residues, phosphorylated by Src in active Src expressing cells, 
changed to phenilalanine ones so this mutant can neither be phosphorylated by nor even 
interact with Src and yet the ability of GST-Cterm to pull down AFAP-1105Y is decreased 
in response to co-expression with active Src in a manner identical to that of wild type 
AFAP-110 (Baisden and Flynn, unpublished data). It has been hypothesized that Src 
activates serine/threonine kinases one of which may be PKC, and these kinases come 
along and phosphorylate AFAP-110 on serine and threonine residues. Indeed, in response 
to PMA treatment the ability of GST-Cterm to pull down AFAP-110 from cell lysates 
decreases in time-dependent manner, and 6 hour treatment of cells co-expressing AFAP-
1105Y and active Src with PKC inhibitor bisindolylmaleimide restores the ability of GST-
Cterm to affinity absorb AFAP-1105Y from cell lysates (Baisden and Flynn, unpublished 
data). 
AFAP-110 has an intrinsic ability to remodel actin filaments as its leucine zipper 
mutant over expression causes actin filament disruption in cultured cells. This ability 
depends upon conformational changes in this protein, which affect its multimerization 
status. AFAP-110 is hyperphosphorylated in Src transformed cells, not only on tyrosine 
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but also on serine and threonine residues (124). Recent data indicates that 
serine/threonine and not tyrosine phosphorylation of AFAP-110 is responsible for 
changes in its self-association (Baisden et al, in preparation).  AFAP-110 is a substrate 
for PKC in vitro and serine/threonine phosphorylated in response to PKC activation in 
vivo (Qian et al, accepted). Non-phosphorylated AFAP-110 cross-links actin filaments 
whereas in response to PKC phosphorylation in vitro it bundles them (Qian et al, 
accepted). Serine/threonine phosphorylation of AFAP-110 alters its function by induction 
of AFAP-110 transition from actin-filament cross-linking to bundling protein. The 
change in AFAP-110 function occurs in response to phosphorylation-dependent alteration 
in its conformation and therefore the ability to self-associate. Recent evidence indicates 
that the site for PKC phosphorylation that mediates this change exists in the 
serine/threonine kinase interaction domain of AFAP-110 (125)(Cherezova and Flynn, 
unpublished observation). PKC activation induces motility structure formation such as 
lamellipodia and filopodia along with disappearance of actin stress fibers. Inside of 
lamellipodia, actin exists as a network of bundles. AFAP-110 therefore may be involved 
in PKC-dependent motility structure formation; upon phosphorylation by PKC AFAP-
110 may act as a protein mediating formation of a meshwork of short actin bundles 
forming a skeleton of growing lamellipodia.  
AFAP-110 therefore is a cellular adaptor protein regulated by serine/threonine 
phosphorylation. Recent data suggest that PKC dependent phosphorylation influences 
AFAP-110 self-association mode and actin filament cross-linking properties. Therefore it 
becomes important to identify AFAP-110 phosphorylation sites playing a crucial role in 
regulation of its function. The strategy and progress in identification of AFAP-110 
functional phosphorylation sites are described in chapter two of this thesis. 
AFAP-110 also contains several sequences that may enable its association with 
another adaptor protein described above, 14-3-3. 14-3-3 proteins are known to act as 
cellular scaffolds bringing signaling proteins into complexes, so if 14-3-3 interacts with 
AFAP-110 it could bring AFAP-110 into proximity with kinases PKC and Raf and 
possibly with other 14-3-3 numerous binding partners. Due to their dimeric nature 14-3-3 
proteins are known to act as allosteric regulators, binding to different parts of the same 
protein. As AFAP-110 contains more than one potential 14-3-3 binding sequence it is 
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likely that 14-3-3 may regulate AFAP-110 conformation in response to cellular signals. 
Chapter three of this thesis describes a strategy and data for determining whether 14-3-3 
is a binding partner for AFAP-110.  
 26
References 
 1.  Muslin, A. J., Tanner, J. W., Allen, P. M., and Shaw, A. S. (1996) Cell 84, 889-
897 
 2.  Tzivion, G., Shen, Y. H., and Zhu, J. (2001) Oncogone 6331-6338 
 3.  Yaffe, M. B., Rittinger, K., Volinia, S., Caron, P. R., Aitken, A., Leffers, H., 
Gamblin, S. J., Smerdon, S. J., and Cantley, L. C. (1997) Cell 91, 961-971 
 4.  Fu, H., Subramanian, R. R., and Masters, S. C. (2000) 
Annu.Rev.Pharmacol.Toxicol. 40, 617-647 
 5.  Yaffe, M. B. and Elia, A. E. (2001) Curr.Opin.Cell Biol. 13, 131-138 
 6.  Lu, P. J., Zhou, X. Z., Shen, M., and Lu, K. P. (1999) Science 283, 1325-1328 
 7.  Verdecia, M. A., Bowman, M. E., Lu, K. P., Hunter, T., and Noel, J. P. (2000) 
Nat.Struct.Biol. 7, 639-643 
 8.  Hofmann, K. and Bucher, P. (1995) Trends Biochem.Sci. 20, 347-349 
 9.  Liao, H., Byeon, I. J., and Tsai, M. D. (1999) J.Mol.Biol. 294, 1041-1049 
 10.  Wang, P., Byeon, I. J., Liao, H., Beebe, K. D., Yongkiettrakul, S., Pei, D., and 
Tsai, M. D. (2000) J.Mol.Biol.  302, 927-940 
 11.  Durocher, D., Henckel, J., Fersht, A. R., and Jackson, S. P. (1999) Mol.Cell 4, 
387-394 
 12.  Durocher, D., Taylor, I. A., Sarbassova, D., Haire, L. F., Westcott, S. L., Jackson, 
S. P., Smerdon, S. J., and Yaffe, M. B. (2000) Mol.Cell 6, 1169-1182 
 13.  van der Voorn L and Ploegh HL (1992) FEBS Lett. 307, 131-134 
 14.  Fuchs, S. Y., Chen, A., Xiong, Y., Pan, Z. Q., and Ronai, Z. (1999) Oncogene 18, 
2039-2046 
 15.  Orian, A., Gonen, H., Bercovich, B., Fajerman, I., Eytan, E., Israel, A., Mercurio, 
F., Iwai, K., Schwartz, A. L., and Ciechanover, A. (2000) EMBO J. 19, 2580-
2591 
 16.  Winston, J. T., Strack, P., Beer-Romero, P., Chu, C. Y., Elledge, S. J., and 
Harper, J. W. (1999) Genes Dev. 13, 270-283 
 17.  Tsvetkov, L. M., Yeh, K. H., Lee, S. J., Sun, H., and Zhang, H. (1999) Curr.Biol. 
9, 661-664 
 18.  Skoulakis, E. M. and Davis, R. L. (1998) Mol.Neurobiol. 16, 269-284 
 27
 19.  Morrison, D. (1994) Science 266, 56-57 
 20.  Burbelo, P. D. and Hall, A. (1995) Curr.Biol. 5, 95-96 
 21.  Baldin, V. (2000) Prog.Cell Cycle Res. 4, 49-60 
 22.  Aitken, A., Jones, D., Soneji, Y., and Howell, S. (1995) Biochem.Soc.Trans. 23, 
605-611 
 23.  Reuther, G. W. and Pendergast, A. M. (1996) Vitam.Horm. 52, 149-175 
 24.  Aitken, A., Collinge, D. B., van Heusden, B. P., Isobe, T., Roseboom, P. H., 
Rosenfeld, G., and Soll, J. (1992) Trends Biochem.Sci. 17, 498-501 
 25.  Jones, D. H., Ley, S., and Aitken, A. (1995) FEBS Lett. 368, 55-58 
 26.  Marais, R. and Marshall, C. (1995) Structure. 3, 751-753 
 27.  Van Der Hoeven, P. C., Van Der Wal, J. C., Ruurs, P., Van Dijk, M. C., and Van 
Blitterswijk, J. (2000) Biochem.J. 345 Pt 2, 297-306 
 28.  Hausser, A., Storz, P., Link, G., Stoll, H., Liu, Y. C., Altman, A., Pfizenmaier, K., 
and Johannes, F. J. (1999) J.Biol.Chem. 274, 9258-9264 
 29.  Aitken, A., Howell, S., Jones, D., Madrazo, J., Martin, H., Patel, Y., and 
Robinson, K. (1995) Mol.Cell Biochem. 149-150, 41-49 
 30.  Tzivion, G., Luo, Z., and Avruch, J. (1998) Nature 394, 88-92 
 31.  Freed, E., Symons, M., Macdonald, S. G., McCormick, F., and Ruggieri, R. 
(1994) Science 265, 1713-1716 
 32.  Freed, E., McCormick, F., and Ruggieri, R. (1994)  Cold Spring 
Harb.Symp.Quant.Biol. 59, 187-193 
 33.  Rommel, C., Radziwill, G., Lovric, J., Noeldeke, J., Heinicke, T., Jones, D., 
Aitken, A., and Moelling, K. (1996) Oncogene  12, 609-619 
 34.  Clark, G. J., Drugan, J. K., Rossman, K. L., Carpenter, J. W., Rogers-Graham, K., 
Fu, H., Der, C. J., and Campbell, S. L. (1997) J.Biol.Chem. 272, 20990-20993 
 35.  Acs, P., Szallasi, Z., Kazanietz, M. G., and Blumberg, P. M. (1995) 
Biochem.Biophys.Res.Commun. 216, 103-109 
 36.  Robinson, K., Jones, D., Patel, Y., Martin, H., Madrazo, J., Martin, S., Howell, S., 
Elmore, M., Finnen, M. J., and Aitken, A. (1994) Biochem.J. 299 ( Pt 3), 853-861 
 37.  Bax, B. and Jhoti, H. (1995) Curr.Biol. 5, 1119-1121 
 28
 38.  Peng, C. Y., Graves, P. R., Thoma, R. S., Wu, Z., Shaw, A. S., and Piwnica-
Worms, H. (1997) Science 277,  1501-1505 
 39.  Kolch, W. (2000) Biochem.J. 351 Pt 2, 289-305 
 40.  Zha, J., Harada, H., Yang, E., Jockel, J., and Korsmeyer, S. J. (1996) Cell 87, 
619-628 
 41.  Kosaki, A., Yamada, K., Suga, J., Otaka, A., and Kuzuya, H. (1998) J.Biol.Chem. 
273, 940-944 
 42.  Dubois, T., Howell, S., Amess, B., Kerai, P., Learmonth, M., Madrazo, J., 
Chaudhri, M., Rittinger, K., Scarabel, M., Soneji, Y., and Aitken, A. (1997) 
J.Protein Chem. 16, 513-522 
 43.  Dubois, T., Rommel, C., Howell, S., Steinhussen, U., Soneji, Y., Morrice, N., 
Moelling, K., and Aitken, A. (1997) J.Biol.Chem. 272, 28882-28888 
 44.  Megidish, T., Cooper, J., Zhang, L., Fu, H., and Hakomori, S. (1998) 
J.Biol.Chem. 273, 21834-21845 
 45.  Bouton, A. H., Riggins, R. B., and Bruce-Staskal, P. J. (2001) Oncogene 20, 
6448-6458 
 46.  Polte, T. R. and Hanks, S. K. (1995) Proc.Natl.Acad.Sci.U.S.A 92, 10678-10682 
 47.  Polte, T. R. and Hanks, S. K. (1997) J.Biol.Chem. 272, 5501-5509 
 48.  Arai, A., Nosaka, Y., Kohsaka, H., Miyasaka, N., and Miura, O. (1999) Blood 93, 
3713-3722 
 49.  Yamakita, Y., Totsukawa, G., Yamashiro, S., Fry, D., Zhang, X., Hanks, S. K., 
and Matsumura, F. (1999) J.Cell Biol. 144, 315-324 
 50.  Honda, H., Oda, H., Nakamoto, T., Honda, Z., Sakai, R., Suzuki, T., Saito, T., 
Nakamura, K., Nakao, K., Ishikawa, T., Katsuki, M., Yazaki, Y., and Hirai, H. 
(1998) Nat.Genet. 19, 361-365 
 51.  Ma, A., Richardson, A., Schaefer, E. M., and Parsons, J. T. (2001) Mol.Biol.Cell 
12, 1-12 
 52.  Chen, H., Slepnev, V. I., Di Fiore, P. P., and De Camilli, P. (1999) J.Biol.Chem. 
274, 3257-3260 
 53.  Kariya, K., Koyama, S., Nakashima, S., Oshiro, T., Morinaka, K., and Kikuchi, 
A. (2000) J.Biol.Chem. 275, 18399-18406 
 54.  Sakakibara, A. and Hattori, S. (2000) J.Biol.Chem. 275, 6404-6410 
 29
 55.  Voltz, J. W., Weinman, E. J., and Shenolikar, S. (2001) Oncogene 6309-6314 
 56.  Weinman, E. J., Steplock, D., Wang, Y., and Shenolikar, S. (1995) J.Clin.Invest 
95, 2143-2149 
 57.  Hall, R. A., Spurney, R. F., Premont, R. T., Rahman, N., Blitzer, J. T., Pitcher, J. 
A., and Lefkowitz, R. J. (1999) J.Biol.Chem. 274, 24328-24334 
 58.  Shenolikar, S., Minkoff, C. M., Steplock, D. A., Evangelista, C., Liu, M., and 
Weinman, E. J. (2001) FEBS Lett.  489, 233-236 
 59.  Lehmann, J. M., Riethmuller, G., and Johnson, J. P. (1990) Nucleic Acids Res. 18, 
1048 
 60.  Li, W., Fan, J., and Woodley, D. T. (2001) Oncogene 20, 6403-6417 
 61.  Meisenhelder, J. and Hunter, T. (1992) Mol.Cell Biol. 12, 5843-5856 
 62.  Li, W., Hu, P., Skolnik, E. Y., Ullrich, A., and Schlessinger, J. (1992) Mol.Cell 
Biol. 12, 5824-5833 
 63.  Han, D. C., Shen, T., and Guan, J. (20 A.D.) Oncogene 20, 6315-6321 
 64.  Dong, L. Q., Porter, S., Hu, D., and Liu, F. (1998) J.Biol.Chem. 273, 17720-
17725 
 65.  Ooi, J., Yajnik, V., Immanuel, D., Gordon, M., Moskow, J. J., Buchberg, A. M., 
and Margolis, B. (1995) Oncogene  10, 1621-1630 
 66.  Daly, R. J., Sanderson, G. M., Janes, P. W., and Sutherland, R. L. (1996) 
J.Biol.Chem. 271, 12502-12510 
 67.  Fiddes, R. J., Campbell, D. H., Janes, P. W., Sivertsen, S. P., Sasaki, H., 
Wallasch, C., and Daly, R. J. (1998) J.Biol.Chem. 273, 7717-7724 
 68.  Glenney, J. R., Jr. and Zokas, L. (1989) J.Cell Biol. 108, 2401-2408 
 69.  Turner, C. E. (2000) Nat.Cell Biol. 2, E231-E236 
 70.  Schaller, M. D. (2001) Oncogene  20, 6459-6472 
 71.  De Nichilo, M. O. and Yamada, K. M. (1996) J.Biol.Chem. 271, 11016-11022 
 72.  Bellis, S. L., Perrotta, J. A., Curtis, M. S., and Turner, C. E. (1997) Biochem.J. 
325 ( Pt 2), 375-381 
 73.  Vadlamudi, R., Adam, L., Talukder, A., Mendelsohn, J., and Kumar, R. (1999) 
Oncogene 18, 7253-7264 
 30
 74.  Ku, H. and Meier, K. E. (2000) J.Biol.Chem. 275, 11333-11340 
 75.  Hashimoto, S., Tsubouchi, A., Mazaki, Y., and Sabe, H. (2001) J.Biol.Chem. 276, 
6037-6045 
 76.  Brown, M. C., Perrotta, J. A., and Turner, C. E. (1998) Mol.Biol.Cell 9, 1803-
1816 
 77.  Schaeper, U., Gehring, N. H., Fuchs, K. P., Sachs, M., Kempkes, B., and 
Birchmeier, W. (2000) J.Cell Biol. 149, 1419-1432 
 78.  Yu, C. F., Roshan, B., Liu, Z. X., and Cantley, L. G. (2001) J.Biol.Chem. 276, 
32552-32558 
 79.  Furge, K. A., Zhang, Y. W., and Vande Woude, G. F. (2000) Oncogene 19, 5582-
5589 
 80.  Roshan, B., Kjelsberg, C., Spokes, K., Eldred, A., Crovello, C. S., and Cantley, L. 
G. (1999) J.Biol.Chem. 274, 36362-36368 
 81.  Gual, P., Giordano, S., Anguissola, S., Parker, P. J., and Comoglio, P. M. (2001) 
Oncogene 20, 156-166 
 82.  Ilan, N., Mahooti, S., Rimm, D. L., and Madri, J. A. (1999) J.Cell Sci. 112 Pt 18, 
3005-3014 
 83.  Ilan, N., Cheung, L., Pinter, E., and Madri, J. A. (2000) J.Biol.Chem. 275, 21435-
21443 
 84.  Ilan, N., Cheung, L., Miller, S., Mohsenin, A., Tucker, A., and Madri, J. A. (2001) 
Dev.Biol. 232, 219-232 
 85.  Shen, Y., Sultana, C., Arditi, M., Kim, K. S., and Kalra, V. K. (1998) 
Am.J.Physiol 275, E479-E486 
 86.  Paasinen-Sohns, A. and Holtta, E. (1997) Oncogene 15, 1953-1966 
 87.  Cherniack, A. D., Klarlund, J. K., and Czech, M. P. (1994) J.Biol.Chem. 269, 
4717-4720 
 88.  Rozakis-Adcock, M., van der, G. P., Mbamalu, G., and Pawson, T. (1995) 
Oncogene 11, 1417-1426 
 89.  Corbalan-Garcia, S., Yang, S. S., Degenhardt, K. R., and Bar-Sagi, D. (1996) 
Mol.Cell Biol. 16, 5674-5682 
 90.  Douville, E. and Downward, J. (1997) Oncogene 15, 373-383 
 31
 91.  Zhao, H., Li, Y. Y., Fucini, R. V., Ross, S. E., Pessin, J. E., and Koretzky, G. A. 
(1997) J.Biol.Chem. 272, 21625-21634 
 92.  Liu, J. P. (1996) Mol.Cell Endocrinol. 116, 1-29 
 93.  Liu, W. S. and Heckman, C. A. (1998) Cell Signal. 10, 529-542 
 94.  Tsygankov, A. Y., Teckchandani, A. M., Feshchenko, E. A., and Swaminathan, 
G. (2001) Oncogene 20, 6382-6402 
 95.  Fernandez, B., Czech, M. P., and Meisner, H. (1999) J.Biol.Chem. 274, 20244-
20250 
 96.  Liu, Y. C., Elly, C., Yoshida, H., Bonnefoy-Berard, N., and Altman, A. (1996) 
J.Biol.Chem. 271, 14591-14595 
 97.  Pedraza-Alva, G., Sawasdikosol, S., Liu, Y. C., Merida, L. B., Cruz-Munoz, M. 
E., Oceguera-Yanez, F., Burakoff, S. J., and Rosenstein, Y. (2001) J.Biol.Chem. 
276, 729-737 
 98.  Liu, Y. C., Liu, Y., Elly, C., Yoshida, H., Lipkowitz, S., and Altman, A. (1997) 
J.Biol.Chem. 272, 9979-9985 
 99.  Staubs, P. A., Nelson, J. G., Reichart, D. R., and Olefsky, J. M. (1998) 
J.Biol.Chem. 273, 25139-25147 
 100.  Li, J., DeFea, K., and Roth, R. A. (1999) J.Biol.Chem. 274, 9351-9356 
 101.  Sun, X. J., Rothenberg, P., Kahn, C. R., Backer, J. M., Araki, E., Wilden, P. A., 
Cahill, D. A., Goldstein, B. J., and White, M. F. (1991) Nature 352, 73-77 
 102.  Mothe, I. and Van Obberghen, E. (1996) J.Biol.Chem. 271, 11222-11227 
 103.  Ogihara, T., Shin, B. C., Anai, M., Katagiri, H., Inukai, K., Funaki, M., 
Fukushima, Y., Ishihara, H., Takata, K., Kikuchi, M., Yazaki, Y., Oka, Y., and 
Asano, T. (1997) J.Biol.Chem. 272, 12868-12873 
 104.  Lam, K., Carpenter, C. L., Ruderman, N. B., Friel, J. C., and Kelly, K. L. (1994) 
J.Biol.Chem. 269, 20648-20652 
 105.  Tanti, J. F., Gremeaux, T., Van Obberghen, E., and Marchand-Brustel, Y. (1994) 
J.Biol.Chem. 269, 6051-6057 
 106.  De Fea, K. and Roth, R. A. (1997) Biochemistry 36, 12939-12947 
 107.  De Fea, K. and Roth, R. A. (1997) J.Biol.Chem. 272, 31400-31406 
 108.  Sasaoka, T. and Kobayashi, M. (2000) Endocr.J. 47, 373-381 
 32
 109.  Luzi, L., Confalonieri, S., Di Fiore, P. P., and Pelicci, P. G. (2000) 
Curr.Opin.Genet.Dev. 10, 668-674 
 110.  Migliaccio, E., Mele, S., Salcini, A. E., Pelicci, G., Lai, K. M., Superti-Furga, G., 
Pawson, T., Di Fiore, P. P., Lanfrancone, L., and Pelicci, P. G. (1997) EMBO J. 
16, 706-716 
 111.  Migliaccio, E., Giorgio, M., Mele, S., Pelicci, G., Reboldi, P., Pandolfi, P. P., 
Lanfrancone, L., and Pelicci, P. G. (1999) Nature 402, 309-313 
 112.  Okada, S., Kao, A. W., Ceresa, B. P., Blaikie, P., Margolis, B., and Pessin, J. E. 
(1997) J.Biol.Chem. 272, 28042-28049 
 113.  Foschi, M., Franchi, F., Han, J., La Villa, G., and Sorokin, A. (2001) J.Biol.Chem. 
276, 26640-26647 
 114.  Yang, C. P. and Horwitz, S. B. (2000) Cancer Res. 60, 5171-5178 
 115.  Kanner, S. B., Reynolds, A. B., Vines, R. R., and Parsons, J. T. (1990) 
Proc.Natl.Acad.Sci.U.S.A 87, 3328-3332 
 116.  Weed, S. A. and Parsons, J. T. (2001) Oncogene 20, 6418-6434 
 117.  Patel, A. S., Schechter, G. L., Wasilenko, W. J., and Somers, K. D. (1998) 
Oncogene 16, 3227-3232 
 118.  Wu, H. and Parsons, J. T. (1993) J.Cell Biol. 120, 1417-1426 
 119.  van Damme, H., Brok, H., Schuuring-Scholtes, E., and Schuuring, E. (1997) 
J.Biol.Chem. 272, 7374-7380 
 120.  Campbell, D. H., Sutherland, R. L., and Daly, R. J. (1999) Cancer Res. 59, 5376-
5385 
 121.  Reynolds, A. B., Kanner, S. B., Wang, H. C., and Parsons, J. T. (1989) Mol.Cell 
Biol. 9, 3951-3958 
 122.  Qian, Y., Baisden, J. M., Zot, H. G., Van Winkle, W. B., and Flynn, D. C. (2000) 
Exp.Cell Res. 255, 102-113 
 123.  Qian, Y., Baisden, J. M., Westin, E. H., Guappone, A. C., Koay, T. C., and Flynn, 
D. C. (1998) Oncogene 16, 2185-2195 
 124.  Kanner, S. B., Reynolds, A. B., Wang, H. C., Vines, R. R., and Parsons, J. T. 
(1991) EMBO J. 10, 1689-1698 


















AFAP-110 was identified as a phosphotyrosine protein that co-
immunoprecipitates with active Src in vSrc-transformed cells (1). Some time later it was 
discovered that AFAP-110 forms a stable complex with Src and also is phosphorylated 
by this tyrosine kinase in in vitro kinase assay (2). Avian form of AFAP-110 was cloned 
in 1993 (3). Immunofluorescence analysis demonstrated that in cultured cells AFAP-110 
co localizes with actin stress fibers as well as with cortical actin matrix. In Src-
transformed cells, which have disassembled actin filaments, AFAP-110 co-localizes with 
actin rosettes or podosomes as well as with the actin underlying dynamic motility 
structures at the leading edge of the cell such as lamellipodia, filopodia, and membrane 
ruffles (3).  
The domain structure of AFAP-110 indicates that this protein may be positioned 
to modulate the effects of signaling proteins upon actin cytoskeleton (figure 1). AFAP-
110 contains several modular domains that mediate its interactions with such signaling 
proteins as Src and PKC. AFAP-110 forms a stable complex with Src via SH2 and SH3 
interactions (4;5); it associates with PKC via amino-terminal PH domain (Baisden and 
Flynn, unpublished data). At the carboxy terminus of AFAP-110 there are also two actin 
binding modules, which are responsible for direct interactions of AFAP-110 with actin 
cytoskeleton (6). AFAP-110 possesses the ability to multimerize via carboxy-terminal 
leucine zipper motif, although the multimerization is not achieved via classical leucine 
zipper interactions. In normal cells AFAP-110 exists in a form of multimeric complexes, 
which range from dimers to hexamers; even larger complexes were observed (7). 
Deletion of carboxy terminal leucine zipper motif results in ability of AFAP-110 to 
disassemble actin filaments into rosette-like structures similar to those, which are seen in 
cells transformed by Src (6;6). AFAP-110, therefore, possesses an intrinsic ability to 
rearrange actin cytoskeleton.  
Recent experiments indicate that AFAP-110 function may be regulated by 
phosphorylation. Even as early as 1991 it was known that in Src transformed cells AFAP-
110 is hyperphosphorylated not only on tyrosine, but also on serine and threonine 
residues (4). That suggested a possibility of Src activating one or several serine/threonine 
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kinases responsible for phosphorylation of AFAP-110. One possible candidate of 
serine/threonine kinase that acts downstream of active Src is protein kinase C. Protein 
kinase C family of serine/threonine kinases are well known modulators of cell growth, 
cell motility and differentiation, also implicated into development and progression of 
certain cancers (8) . PKC superfamily is divided into three subgroups based on their 
structure and the nature of activators: conventional, novel and atypical PKC subfamilies. 
Conventional PKCs are activated by PS, DAG and calcium ions; novel PKCs are 
activated by PS, and DAG but not calcium; atypical PKCs are activated by PS, but 
neither DAG nor calcium (9). DAG pharmacological analogs phorbol esters, for example 
PMA, can also be used to activate conventional and novel PKC isoforms (10). PKCα is 
known to be activated downstream of active Src (11), therefore it has been important to 
test whether AFAP-110 would be a substrate and/or binding partner for this 
serine/threonine kinase. 
It has been determined in recent years that AFAP-110 is a substrate for PKCα in 
vitro, as well as is phosphorylated in PKC-dependent manner in cultured cells. Several 
PKC isoforms, including PKCα are able to associate with AFAP-110 via its amino 
terminal PH domain (Baisden and Flynn, unpublished data). It was also discovered that 
PKC-dependent serine/threonine phosphorylation alters AFAP-110 conformation, which 
in turn results in alterations in AFAP-110 self-association. Phosphorylation by PKCα in 
vitro enhances actin cross-linking ability of recombinant AFAP-110 (Qian et al, 2002). 
Electron microscopy demonstrates that non-phosphorylated AFAP-110 cross-links actin 
filament into a loose meshwork of interconnecting cables, whereas PKC-phosphorylated 
AFAP-110 arranges actin filaments into a more organized network of short bundles (Qian 
et al, 2002). Cumulatively, these data indicate that PKC-dependent phosphorylation 
influences AFAP-110 ability to self-associate and cross-link actin filaments.  Therefore, 
it becomes important to identify phosphorylation sites within AFAP-110 structure that 
are responsible for serine/threonine phosphorylation-induced changes in AFAP-110 
structure and function.  
In order to determine the identity of functional phosphorylation sites within 
AFAP-110 structure we performed phosphotryptic analysis of recombinant AFAP-110 
phosphorylated in in vitro PKC kinase assay as well as that of AFAP-110 derived from 
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cultured cells either treated with PKC stimulator PMA or co-expressing active form of  
Src (Src527F). Phosphotryptic mapping analysis demonstrated that PKCα phosphorylates 
AFAP-110 on multiple residues as well as confirmed previous data that AFAP-110 is a 
substrate for PKCα in vitro. Deletional mutageneses in conjunction with confocal actin 
filament cross-linking assays were employed to determine which regions of AFAP-110 
are most likely to contain functional phosphorylation sites. These experiments indicated 
that the candidate sites are localized to the region encompassed by amino acids 249-294 
of Serine Threonine Kinase Interaction (STK) region. Site directed mutagenesis of 
putative PKC phosphorylation sites is being employed to alter the candidate serine for 
alanine residues. More experiments are necessary to determine whether the serine 
residues within amino acids 249-294 of STK region are the functional phosphorylation 
sites that regulate AFAP-110 self-association and actin cross-linking properties. 
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II. Materials and methods. 
Reagents: DMEM, BME, PMA, bisindolylmaleimide, phosphatidylserine, and 
diolein were purchased from Sigma.  Recombinant PKCα was purchased from 
Calbiochem. Recombinant pp60c-Src was supplied by Upstate Biotechnology.   Anti-
AFAP-110 antibodies 4C3 and F1 were generated as previously described (3;12).  Anti-
GST antibody was supplied by Santa Cruz Biotechnology. Gluthathione sepharose beads 
and PreScission protease were from   Amersham Pharmacia Biotech. CalPhos 
mammalian transfection kit was from Clontech. Lipofectamine 2000 transfection kit and 
PCR Super Mix High Fidelity kit were from Gibco. Quick Change PCR mutagenesis kit 
was supplied by Stratagene. General actin buffer BSA01, actin polymerization buffer 
BSA02, ATP, rhodamine-phalloidin, and rabbit non-muscle actin were supplied by 
Cytoskeleton. GelCode Blue Stain Reagent was from Pierce.  
Cell Culture: Cos-7 cells were maintained in Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 5% Fetal Calf Serum, 2mM glutamine and 1% 
penicillin/streptomycin. 
Expression vectors: pCMV/AFAP-110 and pCMV/AFAP-110/Src527F were 
described in (5;13). pGEX-6p-1-AFAP-110 were described by Qian et al, 2000 (6). 
Primers for deletional mutagenesis: AFAP-110∆62-152 5′ primer was 
GCAGGTACCTGCTGGCAGGCTGTTG; and the 3′ primer was 
ATCGGTACCGATGCCAAAATTTGTGCC. AFAP-110∆PH1 5′ primer was 
AAGGGTACCCTTCACCAGATCCATAGAG; the reverse primer was 
GCTGGTACCAGCAACTGTACGGGCAC. AFAP-110∆STK 5′ primer was 
TGCGGTACCGCACACATCTTTTATAACC; and the reverse primer was 
ATCGGTACCGATGTTCCAACATGTGG. AFAP-110∆PH2 5′ primer was 
GAAGGTACCTTCTTCAGCTGACGAGG; and the reverse primer was 
ATAGGTACCTATGACTATATCGATGTGG. AFAP-110∆249-294 5′ primer was 
TGCGGTACCGCACACATCTTTTATAACC; and the reverse primer was 
CACGGTACCGTGTGCAACGGAAAAG. AFAP-110∆295-346 5′ primer was 
ATCGGTACCGATGTTCCAACATGTGG; and the reverse primer was 
ACAGGTACCTGTGGTGATGCCATTTTCC. AFAP-110∆249-295 5′ primer was 
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TACGGTACCGTACACAAGACAGAGCTG; and the reverse primer was 3′ primer used 
in creating AFAP-110∆249-294 mutant. AFAP-110 ∆ 266-294 5′ primer was the same as for 
AFAP-110∆249-294 5′ primer; and the 3′ primer was 
CCAGGTACCTGGAGAACTAGACAATGG. 
Deletional mutagenesis: pGEX-6p-1-AFAP-110∆62-152, pGEX-6p-1-AFAP-
110∆PH1, pGEX-6p-1-AFAP-110∆STK, pGEX-6p-1-AFAP-110∆PH2, pGEX-6p-1-AFAP-
110∆249-294, pGEX-6p-1-AFAP-110∆295-346, pGEX-6p-1-AFAP-110∆249-265, pGEX-6p-1-
AFAP-110∆266-294 were created by PCR amplification with PCR Super mix High Fidelity 
kit using primers with engineered KpnI restriction site described above (KpnI site 
underlined). Briefly, 45 µl of PCR High Fidelity Mix was mixed with 100 ng of template 
DNA (pGex-6p-1-110) and primers were added to 200nM final concentration; final 
volume of reaction was 50 µl. The reactions were overlaid with 30 µl mineral oil and 
subjected to PCR overnight. PCR machine was programmed according to PCR Super mix 
High Fidelity supplier recommendations, so the reaction was carried out at 94 degrees for 
30 seconds, followed by 35 cycles of 94 degrees for 30 seconds, 55 degrees for 30 
seconds, and 68 degrees for 7 minutes and 30 seconds.   PCR products were digested with 
10 units of KpnI for 2 hours and purified on 0.8% agarose gel. The DNA was then 
transferred by electrophoresis to DEAE membrane, which was subjected to 45-minute 
incubation in 350µl, and consequently 15-minute incubation in 150 µl of High Salt 
DEAE membrane buffer (10.0 ml 5M NaCl, 10.0 ml 0.5M EDTA, 1 ml 1M Tris, 39ml 
MilliQ water) at 65 degrees and then to place DNA into solution. DNA-containing High 
Salt DEAE membrane buffer 350 µl and 150 µl portions were combined, and DNA was 
ethanol precipitated, vacuum dried, and the pellet was dissolved in 16 µl of autoclaved 
MilliQ water. 2 µl of 10X ligation buffer (Roche) and 2 units of T4 DNA ligase (Roche) 
were mixed with the DNA, and the reaction was allowed to proceed at 16 degrees for 16 
hours. 3 µl of ligation reactions were used to transform E. coli DH5α competent cells by 
electroporation. Bacterial cells were then incubated in 1 ml LB Broth at 37 degrees with 
shaking for 1 hour; 20 µl and 200 µl aliquots were plated on 1X Ampicillin LB plates. 
Cultures from several colonies were inoculated for mini-scale DNA preparation, and the 
extracted DNA was screened by restriction mapping to determine which colonies contain 
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pGEX-6P-1-110 plasmid bearing desired deletion.  
Site directed mutagenesis. pCMV/AFAP-110S186,210A, pCMV/AFAP-
110S276,277A, pCMV/AFAP-110S281,282A, and pCMV/AFAP-110S276,277,281,282A  were created 
by PCR-based site-directed mutagenesis using primers with nucleotide mismatches 
containing desired mutation. Briefly, 20 ng of pCMV/AFAP-110 template was mixed 
with 5 ml of 10X reaction buffer (Stratagene), 125 ng of each primer, 1 ul of 10 mM 
dNTP mix (Stratagene), and 2.5 units of Pfu Turbo DNA polymeraze. The volume of 
PCR mix was brought to 50 ml with HPLC grade autoclaved water. The reactions were 
overlaid with 30 ml of mineral oil. The ractions were carried out at 95 degrees for 30 
seconds, and 18 cycles of 95 degrees at 30 seconds, 55 degrees for 1 minute, and 68 
degress for 15 minutes. The reactions were than incubated at 37 degrees for 1 hour with 
10 units of DpnI restriction enzyme (Roche) to digest the template. 1 ul of each PCR 
reaction was added to 50 ul of Epicurian coli XL-1 Blue supercompetent cells and 
incubated on ice for 30 minutes. The transformation reactions were heat-pulsed for 45 
seconds at 42 degrees, and placed on ice for 2 minutes. After that 0.5 ml of NZY-Broth (5 
grams of NZ amine, 2.5 grams of yeast extract, 2.5 grams of NaCl were diluted in 500 ml 
of MilliQ water and autoclaved. 6.25 ml of 1 M MgCl2 and 6.25 ml of 1 M MgSO4 and 5 
ml of a 2M filter-sterilized glucose solution were added to the autoclaved broth, and 
filter-sterilized) preheated to 42 degrees was added to each transformation reaction, and 
the reactions were incubated at 37 degrees with shaking for 1 hour. After that the 
reactions were plated onto 2X Ampicillin LB plates. Cultures from several colonies were 
inoculated for mini-scale DNA preparation, and the extracted DNA was screened either 
by restriction mapping or DNA sequencing to determine which colonies contain 
pCMV/110 plasmid vector bearing desired substitution. 
GST-fusion protein induction: Wild type AFAP-110 or mutants in pGEX-6p-1 
vector were put into E. coli DH5α cells. A starter culture was grown at 37 degrees 
overnight in 50 µg/ml ampicillin LB-Broth media. Starter culture was diluted with fresh 
50 µg/ml ampicillin LB broth in a 1:20 ratio and incubated at 37 degrees with shaking for 
1 hour. IPTG was added to bacterial culture to 0.5 mM concentration. Cultures were 
incubated for 5 hours at 30 degrees with shaking. Bacterial pellets were harvested by 
centrifugation at 6000 rpm for 5 minutes and resuspended in 1%TritonX MT-PBS (150 
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mM NaCl, 16 mM Na2HPO4, 4 mM NaH2PO4, 1% Triton X).  Bacterial cell walls were 
disrupted by sonication, centrifuged at 10000 rpm to separate cell wall debris from lysate. 
Lysate-containing supernatant was collected and stored at –80-degree freezer until 
needed. 
Immobilization of fusion protein on gluthathione sepharose beads: 
Gluthathione sepharose beads were washed into 1% Triton X MT-PBS. GST fusion 
protein lysates were mixed with bead slurry and incubated for 1 hour at 4 degrees with 
shaking. After that the bead-fusion protein complexes were washed in 1% Triton X MT-
PBS and stored at 4 degree refrigerator for future use. 
Cleavage of proteins from GST - gluthathione sepharose beads complexes: 
Bead-GST-fusion protein complexes were washed into PreScission protease cleavage 
buffer (50mM Tris, 150 mM NaCl, 1 mM EDTA, 1mM DTT). For each ml of washed 
Gluthathione Sepharose bed volume 80 units of PreScission protease were mixed with 
PreScission protease cleavage buffer, and the mixture was added to the beads. Cleavage 
was allowed to proceed for 16 hours at 4 degrees. Protein-containing supernatant was 
collected and stored at –20-degree freezer for future use. 
Dialysis and concentration of recombinant proteins: Recombinant proteins in 
PreScission cleavage buffer were placed into dialysis membrane bags and incubated for 
24 hours in a dialysis buffer (5 mM Tris, 0.2 µM CaCl2) with gentle stirring at 4 degrees. 
Dialyzed proteins were concentrated using Microcon concentration tubes. Concentration 
proceeded by sequential centrifugation of 500 µl aliquots of dialysed protein samples at 
11000 rpm for 10 minutes. The concentrated protein solution was collected by 
centrifugation at 2000 rpm for 5 minutes. The yield was determined by resolving 1 µl 
aliquots of recombinant protein on a 8% SDS-PAGE with BSA molecular weight 
standards followed by staining of gel with GelCode Blue Stain Reagent. 
In vitro phosphotryptic mapping: GST-AFAP-110 bound to gluthathione 
sepharose beads was washed into PKC assay buffer (20 mM Tris, pH 7.5, 5 mM MgCl2, 
0.2 mM CaCl2, 20 µg/ml phosphatidylserine, 2µg/ml diolein). 5µg of recombinant PKCα 
and 200 µCi 32P-γ-ATP were added per 1 ml of beads with recombinant protein into the 
reaction tube, and in-vitro phosphorylation was allowed to proceed for 2 hours at 30-
degree incubator with shaking. Gluthathione sepharose bead slurry was washed into pre-
 41
scission protease cleavage buffer, 80 units of PreScission protease were added per ml of 
washed Gluthathione Sepharose bed volume, and cleavage proceeded for 16 hours at 4 
degrees with shaking. Supernatant, containing 32P-γ phosphorylated protein, was 
collected, and protein was precipitated with 250 µl ice cold TCA using 20 µg of RNase A 
as a carrier protein. The pellet was washed with ethanol, air dried, resuspended in 100 µl 
of 2XLSB, boiled for 5 minutes and subjected to 8 % SDS-PAGE. SDS-PAGE with 32P-γ 
phosphorylated protein in it was exposed to film and radioactive band was excised. 
Radioactively labeled protein was eluted out of acrylamide with two changes of 500 µl 
50mM NH4HCO3 with 50 µl 2ME and 10 µl 10 % SDS. Radiolabeled protein was TCA 
precipitated as described above. Immobilized trypsin was washed into 50mM NH4HCO3 
buffer and mixed with TCA precipitated radiolabeled protein. Tryptic digestion was 
allowed to proceed in 37-degree incubator for 16 hours. Phosphotryptic peptide 
containing supernatant was collected and lyophilized. The pellet was washed and 
lyophilized twice in milliQ water, resuspended in 6 µl buffer pH=1.9 (50 ml 88% formic 
acid, 156 ml glacial acetic acid, 1794 ml MilliQ water) and loaded on TLC plates. 
Samples were run via electrophoresis for 1 hour at 1kVolts in a pH=1.9 buffer in first 
dimension, then for 16 hours in a chromatography buffer optimized for phosphopeptides 
(750 ml n-butanol, 607 ml pyridine, 150 ml glacial acetic acid, 600 ml MilliQ water) in 
the second dimension using the HTLE7000 system, according to manufacturers 
instructions. TLC plates with two-dimentionally separated phosphotryptic peptides were 
exposed to phosphorimager cassettes for at least 16 hours. Radioactive spots 
representative of phosphotryptic peptides were analyzed using phosphorimager.   
In vivo phosphotryptic mapping:  For PMA treatment, Cos-7 cells were grown 
to 60% confluence in 100 mm culture dishes, transiently transfected with pCMV/AFAP-
110 or pCMV/AFAP-110/Src527F using CalPhos transfection kit, serum starved overnight 
in the presence of 2.5 mCi of radioactive orthophosphate, then stimulated with 100 nM 
PMA for 1 hour.  To determine effects of activated Src on AFAP-110, Cos-7 cells were 
grown to 60% confluence in 100 mm culture dishes, transiently transfected with 
pCMV/AFAP-110/Src527F plasmid and labeled with 2.5 mCi of radioactive 
orthophosphate. 60-66 hours after transfection cells were washed twice with PBS and 
lysed with 1 ml RIPA lysis buffer (1% NP-40, 0.25 % deoxycholate, 150mM NaCl, 
 42
50mM Tris, pH=7.5) supplemented with protease and phosphatases inhibitors (50 µg/µl 
aprotinin, 2mM Sodium Vanadate, 2mM PMSF, 2 mM EGTA, 10 µg/ml Leupeptin).   2 
µl monoclonal antibody 4C3 was used to immunoprecipitate AFAP-110 from the Cos-7 
lysate. 30 µl of protein A agarose was used as a secondary antibody to pull down 4C3-
AFAP-110 complexes. Immunoprecipitates were resuspended in 2X LSB, boiled and 
subjected to 8% SDS-PAGE.  From this step the experiment proceeded as described in in 
vitro phosphotryptic mapping protocol.  
In vitro PKC kinase assay: 0.4 µg of recombinant protein (AFAP-110 or mutant) 
was mixed with 0.2 µg of human recombinant PKCα in the presence of 2.5 nanomoles 
ATP in a PKC assay buffer (20 mM Tris, pH 7.5, 5 mM MgCl2, 0.2 mM CaCl2, 20 µg/ml 
phosphatidylserine, 2µg/ml diolein). The reactions were incubated at 30 degrees for 30 
minutes.  
In vitro Src kinase assay for in vitro phosphotryptic mapping: GST-AFAP-
110 bound to gluthathione sepharose beads was washed into Src kinase buffer (100mM 
Tris-HCl, pH=7.2, 125 mM MgCl2, 25mM MnCl2, 2mM EGTA, 0.25mM sodium 
orthovanadate, 2mM dithiothreitol). 30 units (10 µl) of recombinant Src kinase and 200 
µCi of 32P-γ-ATP were added to the reaction tube already containing gluthathione 
sepharose beads with GST-AFAP-110 in Src kinase buffer. The phosphorylation reaction 
was allowed to proceed for 2 hours at 30 degrees with shaking. 
Confocal microscopy actin cross-linking assays: Rabbit nonmuscle G actin was 
resuspended in general actin buffer BSA01 to concentration 50 ug/ul (5mM Tris, pH=8.0; 
0.2mM CaCl2), snap-frozen in liquid nitrogen and kept at –80-degree freezer until 
needed.  2µM F-actin stock was prepared from G-actin in 5mM Tris-HCl pH 8.0, 0.2mM 
CaCl2, 0.5 mM DTT, 100mM MgCl2, and 50mM ATP at room temperature for 1 hour. 
Then F-actin was labeled with rhodamine-phalloidin by incubating F-actin with 0.5 µg/µl 
rhodamine-phalloidin in proportion 9:1 for 3 hours at 4 degrees.  Rhodamine-phalloidin-
labeled F-actin was mixed with recombinant AFAP-110 or AFAP-110 mutants, either 
phosphorylated or non-phosphorylated by PKC in vitro, in 5mM MgCl2, 1mM EGTA, 
2mM ATP, 50mM KCl at room temperature for 30 minutes. After the incubation, 
reactions were placed on the glass slides, covered with coverslips, sealed and analyzed 
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under Zeiss LSM 510 confocal microscope. 
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III. Results. 
Previous data indicates that AFAP-110 is a substrate for PKC in vitro and is 
phosphorylated on serine and threonine residues in vivo in response to treatment of 
cultured cells with phorbol ester PMA or co-expression of active Src. Serine/threonine 
phosphorylation alters AFAP-110 ability to self-associate and enhances its actin cross-
linking capability (Baisden and Flynn, unpublished data; Qian et al, 2002, MBC). 
Therefore it becomes important to identify AFAP-110 phosphorylation sites, which play 
a pivotal role in regulation of AFAP-110 function. 
We started to approach phosphorylation sites identification using phosphotryptic-
mapping analysis of recombinant AFAP-110 according to the protocol described by 
Boyle and co-workers (14). Recombinant AFAP-110 was incubated with human 
recombinant PKCα in vitro at a molar ratio of 20:1 substrate to enzyme in the presence of 
radioactive ATP in PKCα kinase buffer containing co-factors for cPKC. Phosphorylated 
AFAP-110 was then purified on 8% SDS-PAGE, eluted out of acrylamide and digested 
with trypsin.  Phosphotryptic peptides were subjected to two-dimensional separation on 
TLC plates, which were then analyzed using phosphorimager. 
Phosphotryptic mapping analysis of recombinant AFAP-110 revealed that 14 
phosphotryptic fragments are generated in response to AFAP-110 phosphorylation by 
PKCα in vitro. This experiment confirmed that AFAP-110 is a substrate for PKCα in 
vitro and also demonstrated that PKCα phosphorylates AFAP-110 on multiple residues. 
Figure 2A.    
In order to determine whether any of these fragments are generated in response to 
PKC activation in vivo, Cos-1 cells transiently expressing AFAP-110 were radiolabeled 
with 32P-orthophosphate and subjected to 1-hour treatment with 100nM phorbol-12-
myristate-13-acetate (PMA) to activate PMA-inducible PKC isoforms. Also, Cos-1 cells 
were transiently co-transfected with AFAP-110 and active form of non-receptor tyrosine 
kinase Src (Src527F), which is known to activate PKCα (11); these cells were also 
radiolabeled with 32P-orthophosphate. AFAP-110 was pulled down from these cells by 
immunoprecipitation with anti-AFAP-110 antibody 4C3, gel purified, and digested with 
trypsin. Phosphotryptic peptides were subjected to two-dimensional separation on TLC 
plates (Figure 2, B and C). Only six phosphotryptic fragments appear on both in vivo 
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maps (Figure 2, B and C), four of which are common to both in vivo maps (indicated by 
arrowheads). Comparison of the three maps (Figure 2, A, B and C) reveals the presence 
of two common fragments among them (indicated by black arrowheads).  Both in vivo 
maps (B and C) contain two phosphotryptic fragments (indicated by white arrowheads), 
which are not present on in vitro map (A). These fragments may represent peptides that 
are actually present on in vitro map, but positioned differently on in vivo maps due to in 
vivo posttranslational modifications other than phosphorylation, which affect their 
molecular weight and/or hydrophobicity. Alternatively, these fragments may be 
generated in response to phosphorylation of AFAP-110 by PKC or other PMA activated 
serine/threonine kinases on residues, which are not phosphorylated by recombinant 
PKCα in vitro. One more explanation of the differences among fragments from in vitro 
and in vivo maps could be that in vivo derived peptides may also be phosphorylated on 
tyrosine residues, especially in cells co-expressing active form of Src, which would 
therefore result in change of their mobility in both dimensions on TLC plates. Neither 
peptide on maps B nor C represents a phosphotryptic fragment phosphorylated only on 
tyrosine residues, as no phosphotryptic peptide on maps B and C migrates in the same 
manner as the AFAP-110 tryptic fragment(s) phosphorylated with recombinant Src in 
vitro (Figure 2 D).  
Previous data of Qian et al (Qian et al, 2002) indicates that AFAP-110 is an actin 
cross-linking protein, and that phosphorylation by PKC enhances actin cross-linking 
properties of AFAP-110. Qian et al used confocal microscopy actin filament cross-
linking assays as well as AFAP-110 and actin filament low speed co-sedimentation 
assays to obtain their data. For confocal actin filament cross-linking assay filamentous 
actin was prepared in vitro and labeled with rhodamine-phalloidin, and then it was 
incubated either alone or with non-phosphorylated or phosphorylated AFAP-110. 
According to Qian et al, in the absence of actin cross-linking protein actin appears 
uniformly fluorescent, whereas in the presence of non-phosphorylated AFAP-110 actin 
filament become organized into a pattern of interconnecting fluorescent cables. In the 
presence of PKC phosphorylated AFAP-110 actin appears in a form of large bright 
aggregates of fluorescence, which are representative of tightly organized actin filaments, 
with a dark spaces among them (Qian et al, 2002). These data along with the data from 
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actin pelleting assays (Qian et al, 2002) indicates actin cross-linking properties of AFAP-
110 are regulated by serine/threonine phosphorylation and accentuates the importance of 
determining the identity of these sites.  
PKC consensus site is represented by serine or threonine residue in a position 0 
with a basic amino asid(s) lysine or arginine in a position –4, -3, -2 and/or +2, +3, +4 








AFAP-110 phosphotryptic fragment containing 
putative PKC site(s) 
1 10 - 25  LFLELLDHEYLTSTVR 
2 38 - 42 …NILLR IQSSK 
3 53 -104  ………IPQQWLPPDNGPPPLPTSSLPEGYYEEAVPVSPGK 
4 186 - 188 LLCYK SSK 
5 209 - 211 …DCSITYIPK DSK 
6 246 - 268 VIK DVCSNCTGTVDSDGPLSSSPVHK 
7 275 - 299 TELEKK LSSERPSSDGEGAVENGITTVCNGK 
8 307 - 309 RKK SSK 
9 319 - 322 GTVTK VTGK 
10 405 - 410  HPLTFR 
11 485 - 512 VISTNPYR GSTANGYACPSGMALHYDDVPCINGSFK 
12 515 - 526  KPPATANGITGK 
13 642 - 645 LTEVK ESLK 
 
Therefore it would not be worthwhile to employ site directed mutagenesis before 
it has been determined which region of AFAP-110 is most likely to contain functional 
sites of phosphorylation. In order to determine which regions of AFAP-110 are most 
likely to contain functional AFAP-110 phosphorylation sites responsible for 
phosphorylation-dependent change in actin cross-linking ability of this protein PCR-
based deletional mutagenesis was performed. GST-tagged AFAP-110 mutants missing 
amino acids 62-152 (SH3 binding, potential WW, SH2 binding motifs), 153-248 
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(PH1domain), 249-346 (Serine threonine kinase interaction region), and 347-450 (PH2 
domain) were created (Figure 3).  
GST-tagged recombinant AFAP-110 bearing each of these deletions was made in 
bacteria, purified on gluthathione sepharose beads, and digested from gluthathione 
sepharose bound GST portion with preScission protease. AFAP-110 was then dialyzed 
and concentrated on microcon concentrating tubes. Full-length AFAP-110 and deletion 
mutants were phosphorylated by recombinant PKCα in vitro, and incubated with 
rhodamine-phalloidin labeled filamentous actin. The reactions were analyzed by confocal 
microscopy actin cross-linking assays developed by Qian and colleagues (Qian et al, 
2002). In the presence of non-phosphorylated AFAP-110 actin filaments are organized 
into a network of interconnecting fluorescent filaments (Figure 4 A and B), whereas 
confocal microscopy image of actin filaments incubated with PKC-phosphorylated 
AFAP-110 demonstrates appearance of large bright aggregates of fluorescence 
representative of tighter cross-linked actin filaments (figure 4 C and D). These data 
repeated the results of Qian et al (Qian et al, 2002) indicating that phosphorylated AFAP-
110 cross-links actin filaments much more efficiently than non-phosphorylated. Confocal 
actin cross-linking assay therefore may be used as an in vitro test for AFAP-110 function. 
Confocal analysis of PKCα-phosphorylated versus non-phosphorylated AFAP-110 
mutants demonstrates that three out of four deletions alter actin cross-linking properties 
of AFAP-110. When AFAP-110 mutant, missing SH3 binding motif, potential WW motif 
and amino terminal SH2 binding motif  (AFAP-110∆62-152), phosphorylated by PKCα in 
vitro is incubated with rhodamine-labeled filamentous actin, most of the actin filaments 
appear in a form of network, with few actin aggregates scattered all over slide area 
(Figure 5).  
Deletion of SH3 binding, potential WW, and SH2 binding regions of AFAP-110 
therefore reduces PKC ability to enhance actin cross-linking properties of AFAP-110, but 
does not eliminate it completely. AFAP-110 mutant missing amino terminal PH domain 
(AFAP-110∆PH1) loses the ability to cross-link actin efficiently in response to PKCα 
phosphorylation (Figure 6 C and D), but the incubation of actin filaments with non-
phosphorylated PH1 deletion mutant results in appearance of bright actin aggregates 
indicative of efficient actin filament cross-linking by this construct (Figure 6 A and B). 
 48
AFAP-110∆PH1 therefore can cross-link actin filaments efficiently in the absence of 
phosphorylation, in the same manner as PKC phosphorylated full length AFAP-110, 
however, in response to phosphorylation it can only cross-link filamentous actin into a 
loose network similar to non-phosphorylated full length AFAP-110.   
Rhodamine-labeled actin filaments incubated with phosphorylated AFAP-110 
mutant missing serine/threonine kinase interaction region  (AFAP-110∆STK) appear 
exactly the same was as F-actin incubated with non-phosphorylated mutant; they are 
arranged into network of fluorescent fibrils with no bright actin aggregates at all (Figure 
7). Phosphorylation by PKCα fails to enhance actin cross-linking ability of this deletion 
mutant. The data presented in Figure 7 indicate that the integrity of STK region is 
important for PKC-phosphorylation-dependent regulation of AFAP-110 function. There 
are two possible hypotheses as to why AFAP-110∆STK fails to cross-link filamentous actin 
into a tighter aggregates in response to phosphorylation by PKCα. One of them is that 
AFAP-110 may undergo a conformational change as a result of deletion of amino acids 
249-346 in a way that this protein can no longer associate with and/or be phosphorylated 
by PKCα. Another one is that STK region of AFAP-110 contains functional 
phosphorylation sites within its structure, and it is their disappearance that results in 
inability of PKCα to alter AFAP-110∆STK actin filament cross-linking properties.  
AFAP-110 mutant missing carboxy terminal PH domain (AFAP-110∆PH2) behaves 
in the same manner as the full length AFAP-110 (Figure 8). Non-phosphorylated AFAP-
110∆PH2 cross-links actin filaments into loosely interconnecting actin cables (Figure 8 A).  
Phosphorylation by PKCα enhances the ability of AFAP-110∆PH2 mutant to efficiently 
cross-link actin filaments into tighter aggregates (Figure 8 B). Deletion of carboxy 
terminal PH domain does not seem to have any effect on PKC-phosphorylation-
dependent ability of AFAP-110 to cross-link actin filaments, and therefore PH2 domain 
is hardly likely to contain functional phosphorylation sites. 
AFAP-110∆STK completely loses the ability to efficiently cross-link actin in 
response to phosphorylation by PKCα. Therefore STK region of AFAP-110 may contain 
functional phosphorylation sites within its structure. There are several putative PKCα 
target sites within this region (Table 1). Before we attempt to change them all at once, 
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one by one or in combinations by site-directed mutagenesis, we decided to narrow down 
the area even further and create two more deletion mutants.  
In attempt to discover whether it is a matter of phosphorylation sites, two more 
deletion mutants were created: GST-tagged AFAP-110 missing amino acids 249-294 
(first half of STK region) and amino acids 295-346 (second half of STK region) (Figure 
9). These mutants were also expressed in bacterial cells, purified as described above, 
phosphorylated by PKCα in vitro and incubated with rhodamine-phalloidin labeled actin 
filaments and analyzed using confocal microscope.  
Actin filaments incubated with PKC-phosphorylated AFAP-110∆249-294 appear as 
a network of fluorescent cables, same as F-actin incubated with non-phosphorylated 
AFAP-110∆249-294 mutant or wild type (Figure 10).   
PKC-phosphorylated AFAP-110∆295-346 is able to cross-link actin into a large 
bright fluorescent aggregates in a same manner as PKC phosphorylated full length 
AFAP-110, whereas non-phosphorylated AFAP-110∆295-346 behaves exactly as the full 
length AFAP-110 (Figure 11). These data suggest that the integrity if the amino-terminal 
half of STK region is the most important for PKC-dependent regulation of AFAP-110 
actin cross-linking ability. The first half of STK region therefore may contain the 
phosphorylation sites crucial for the regulation of AFAP-110 function by serine/threonine 
phosphorylation. In an attempt to further narrow down the AFAP-110 region containing 
functional serine/threonine phosphorylation sites, two more deletion mutants were 
created by PCR-based deletional mutagenesis.  
These AFAP-110 mutants miss either amino acids 249-265 (first quarter of STK 
region) or amino acids 266-294 (second quarter of STK region) (Figure 12). GST-tagged 
AFAP-110∆249-265 and AFAP-110∆266-294 were expressed in bacterial cells, purified, 
cleaved off GST portion, dialyzed, concentrated and phosphorylated by PKCα in vitro. 
Rhodamine labeled actin filaments were incubated with PKC phosphorylated versus non-
phosphorylated these mutants. Results of this experiment are shown in figures 13 and 14.  
Non-phosphorylated AFAP-110∆249-265 and AFAP-110∆266-294 cross-link actin in 
the same manner as non-phosphorylated full length AFAP-110 (Figures 13 and 14, panels 
A). Actin filaments incubated with phosphorylated forms of these mutants mostly 
organized into network of fluorescent bundles with very few bright aggregates of more 
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tightly cross-linked actin (Figure 13 and 14, panels B). There are fewer of these 
aggregates in case of PKC-phosphorylated AFAP-110∆266-294 (Figure 14 B) rather than in 
case of PKC-phosphorylated AFAP-110∆249-265 (Figure 13 B). These data suggest that 
more important functional phosphorylation sites are localized to amino acids 266-294 
within STK region. Incomplete loss of AFAP-110∆266-294 to efficiently cross link actin 
upon PKC phosphorylation suggests that multiple phosphorylation sites may be 
responsible for this, and some of them may be localized to amino acids 249-265. There 
are four serine residues within second quarter of STK region – S276, 277, 281 and 282. 
They all fall into definition of PKC phosphorylation sites. They will be mutated to 
alanine residues in pairs or all at once, and various experiments will be performed to 
determine whether these are the functional phosphorylation sites. 
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IV. Discussion. 
AFAP-110 is a multidomain adaptor protein, which was discovered as a Src-
associated tyrosine phosphorylated protein (2). AFAP-110 domain structure suggests that 
this protein can be positioned to alter actin cytoskeleton in response to cellular signals. 
Indeed, AFAP-110 binds Src directly via SH2- and SH3 binding motifs, and also 
interacts with PKC via its amino-terminal PH domain; AFAP-110 has the ability to bind 
actin directly via its carboxy-terminally located actin binding modules (16). AFAP-110 
also has the ability to self-associate via leucine zipper interactions; gel filtration analysis 
of cellular AFAP-110 demonstrated that in normal cells AFAP-110 is present mostly in 
the form of large complexes like tetramers, pentamers or hexamers or even larger ones. In 
response to co-expression with active Src it exists predominantly in a form of dimers (7). 
AFAP-110 has an intrinsic ability to remodel actin cytoskeleton as the deletion of leucine 
zipper motif enables this protein to cause disorganization of actin stress fibers into actin 
rosettes similar to ones often seen in cells expressing active Src; AFAP-110∆lzip also 
induces lamellipodia and filopodia formation (6). Previous data have shown that AFAP-
110 may be regulated by serine/threonine phosphorylation in response to activation of 
cellular kinases Src and PKC.  AFAP-110 is a substrate for PKCα in vitro and is 
phosphorylated in response to PKC activation in vivo (Baisden and Flynn, unpublished 
data). Serine/threonine phosphorylation is thought to cause alterations in AFAP-110 
conformation, which are responsible for changes in its multimerization status. Recently it 
was determined that large multimeric complexes formed by non-phosphorylated AFAP-
110 are thought to cross-link actin filaments in a loose manner, promoting assembly of a 
meshwork of cross-linked actin filaments, whereas AFAP-110 dimers formed by 
serine/threonine phosphorylated protein arrange actin filaments into more dense 
structures which can be described as a networks of short tight actin bundles (Qian et al, 
accepted). Activation of cellular kinase PKC promotes actin stress fibers disassembly but 
in the same time induces actin filament organization into a meshwork of cross-linked 
short bundles, which act as a skeleton for lamellipodia. AFAP-110 is a protein that may 
act as a PKC effector responsible for those changes, and its ability to rearrange actin is 
regulated by serine/threonine phosphorylation. Therefore it became important to identify 
phosphorylation sites within AFAP-110 structure that are responsible for changes in 
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AFAP-110 conformation, self-association status and actin cross-linking ability of this 
protein. 
Fist of all, AFAP-110 was subjected to phosphotryptic mapping analysis. 
Phosphotryptic map of in vitro PKC phosphorylated recombinant AFAP-110 reveals 
presence of fourteen spots which indicate that PKC phosphorylates AFAP-110 on 
multiple residues and also confirms data of Baisden and Flynn that AFAP-110 is a 
substrate for PKC in vitro. Phosphotryptic maps of in-vivo derived AFAP-110 purified 
from cultured cells either treated with PMA or co-expressed with active Src demonstrate 
lesser number of phosphotryptic fragments but nonetheless confirm that AFAP-110 is 
phosphorylated in vivo in PKC dependent manner. Each in vivo map reveals the presence 
of six fragments total, four of which coincide between the two in vivo maps suggesting 
that most of the fragments on in vivo map of AFAP-110 over expressed with active Src 
are serine/threonine phosphorylated fragments. Two fragments (indicated by black 
arrowheads on figure 2) are common between the in vivo maps and the recombinant 
AFAP-110 phosphorylated by PKC in vitro map suggesting that those two fragments 
must be phosphorylated by PKC in vivo. There are fragments present on in vivo 
phosphotryptic maps, which are absent from in vitro phosphotryptic map; their different 
mobility in both dimensions may be explained by the presence of posttranslational 
modifications other than phosphorylation in AFAP-110 purified from mammalian cells 
and/or by the fact that those fragments are phosphorylated on tyrosine residues as well.  
Phosphotryptic mapping, although a useful technique, cannot provide us with an 
answer which serine/threonine residues within AFAP-110 structure are phosphorylated in 
response to PKC activation. When we analyze AFAP-110 amino acid sequence, we find 
that AFAP-110 contains over twenty potential PKC phosphorylation sites (table 1). It 
would not be rational to try to change all these serine or threonine residues one by one or 
in combinations until we know which regions of AFAP-110 are most likely to contain 
functional phosphorylation sites. In order to identify the region(s) of AFAP-110 
containing functional serine/threonine phosphorylation sites we have decided to use 
deletional mutagenesis in conjunction with an actin filament cross-linking assays as a test 
for AFAP-110 function developed by Yong Qian  (described in Qian et al, accepted).  
At first, four deletion mutants missing either amino-terminally located SH3- 
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binding, potential WW-binding and SH2- binding motifs, amino terminal PH domain, 
STK region or carboxy-terminal PH domain were created and tested for the ability to 
cross-link filamentous actin in response to PKC phosphorylation in vitro. AFAP-110 
mutant missing amino-terminally located SH3- binding, potential WW-binding and SH2- 
binding motifs (AFAP-110∆62-152) demonstrated a partial loss of ability to cross-link actin 
efficiently in response to PKC phosphorylation in vitro, but not the complete inability to 
cross-link actin filaments into the tight aggregates (figure 5), whereas AFAP-110 mutant 
missing carboxy-terminal PH domain (AFAP-110∆PH2) behaved in the same manner as 
the full length AFAP-110, displaying an increase in actin cross-linking ability upon 
PKCα-phosphorylation. AFAP-110∆PH1 mutant on the other hand displayed a peculiar 
behavior. In the absence of PKCα phosphorylation this mutant cross-linked actin 
filaments as efficiently as PKCα phosphorylated wild type AFAP-110, whereas 
phosphorylated AFAP-110∆PH1 could only loosely cross-link filamentous actin in a 
manner resembling that of wild type non-phosphorylated AFAP-110, and did not bring 
actin filaments into tight aggregates. This behavior of PH1 deletion mutant may be 
explained by the fact that amino terminal PH domain participates in AFAP-110 self-
association.  PH1 is known to interact with carboxy terminal leucine zipper motif; these 
interactions are thought to stabilize AFAP-110 multimerization (Qian et al, accepted).  
Deletion of carboxy terminal leucine zipper motif results in ability of AFAP-110 to 
efficiently cross-link actin without PKCα phosphorylation in confocal actin filament 
cross-linking assays (Qian et al, accepted). It has been determined by Qian and 
colleagues that full length AFAP-110 exists in a form of nanomers in actin buffer, 
whereas AFAP-110 missing leucine zipper motif is found only in a form of trimers (Qian 
et al, accepted). Therefore we hypothesize that deletion of amino terminal PH domain of 
AFAP-110 results in a loss of an opposing binding site for leucine zipper motif, therefore 
AFAP-110 may not have been able to form multimers larger than dimers or trimers, and 
so the changed state of multimerization may have been responsible for the ability of 
AFAP-110∆PH1 to cross-link actin filaments efficiently on its own. Surprisingly, PKCα 
phosphorylation of AFAP-110∆PH1 mutant down-regulates its actin cross-linking ability. 
We do not know why that occurs, it may be that phosphorylation of AFAP-110∆PH1 
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mutant induces a conformational change in this protein so that it can no longer form 
dimers or trimers, AFAP-110 may only exist in a form of monomers or conversely, 
phosphorylation of this particular mutant may alter its conformation in a way that 
formation of larger complexes becomes possible. Additional experiments are needed to 
determine multimerization status of AFAP-110∆PH1 in PKCα-phosphorylated versus non-
phosphorylated states.  
 AFAP-110∆STK mutant demonstrated a complete loss of PKCα- induced ability to 
cross-link actin filaments efficiently into tight aggregates. This mutant, whether 
phosphorylated or non-phosphorylated, could only loosely cross-link actin filaments in a 
manner identical to that of non-phosphorylated wild type AFAP-110. There are two 
possible explanations why this has happened: one of them is that STK region contains 
pivotal PKC phosphorylation sites responsible for AFAP-110 regulation in response to 
serine/threonine phosphorylation; another explanation may be that the deletion of STK 
region caused a change in AFAP-110 conformation so AFAP-110∆STK mutant could no 
longer associate with and/or be phosphorylated by PKCα. There is a strong indication 
that AFAP-110 inability to efficiently cross-link actin in response to phosphorylation 
occurs due to the first reason because STK region contains nine serine and threonine 
residues which fall into definition of PKC consensus sites (table 1, fragments 6-9).  
In order to narrow down the area of investigation further two more AFAP-110 
deletion mutants were created - missing either first or second half of STK region, called 
AFAP-110∆249-294 and AFAP-110∆295-346, missing six and three potential PKC 
phosphorylation sites, respectively. Both mutants were tested in confocal in vitro actin 
filament cross-linking assays to determine the effects of each deletion on the ability of 
PKCα to enhance actin filament cross-linking properties of AFAP-110. AFAP-110∆249-294 
behaved exactly as AFAP-110∆STK - in other words it failed completely to cross-link 
filamentous actin efficiently in response to PKCα phosphorylation, whereas actin 
filaments cross-linking ability of AFAP-110∆295-346 was enhanced in response to PKCα 
phosphorylation in the same manner as in case of the full length AFAP-110. Therefore 
we conclude that the amino terminal half of serine threonine kinase interaction domain of 
AFAP-110 is the region the integrity of which is important for PKC-dependent regulation 
of AFAP-110 function, and that the functional phosphorylation sites are most likely to 
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reside within this region. There are six potential PKC phosphorylation sites within amino 
acids 249-294; so in order to narrow down the area even further two more deletion 
mutants were made- AFAP-110 missing either first quarter (AFAP-110∆249-265) or second 
quarter (AFAP-110∆266-294) of STK region. These mutants were tested for their ability to 
cross-link actin with or without PKCα phosphorylation in confocal actin cross-linking 
assays. The results of the first experiment have shown that both mutants demonstrate 
partial loss of ability to efficiently cross-link actin upon PKCα phosphorylation (figures 
13 and 14).  Confocal data is qualitative rather than quantitative, but our rough estimate is 
the ability of AFAP-110 to display enhanced actin filament cross-linking upon 
phosphorylation is diminished up to 90 per cent whereas the ability of AFAP-110 to 
display enhanced actin filament cross-linking upon phosphorylation is diminished only 
up to 50 or 60 per cent. These experiments must be repeated in order to confirm the 
accuracy of the first experiment described here. Nonetheless, the data of confocal actin 
cross-linking assays performed with AFAP-110 deletion mutants described above points 
out that phosphorylation sites playing role in regulation of AFAP-110 function must 
reside within amino acids 266-294 of STK region. Serine residues 276,277,281 and 282 
are the strongest candidates to be PKCα functional phosphorylation sites. AFAP-110 
point mutants having either first or second pair of these serines changed to alanines have 
already been created in our lab as well as AFAP-110 mutant, which has all four of these 
serine residues mutated to alanines. These mutants are going to be tested in confocal actin 
cross-linking assays in order to determine whether they would fail to cross-link 
filamentous actin efficiently in response to PKCα phosphorylation in vitro, and also these 
mutants along with described above AFAP-110 deletion mutants will be expressed in 
cultured cells to determine whether their expression would block actin cytoskeleton 
reorganization and motility structure formation induced in response to PKC activation. 
 56








Figure 1. AFAP-110 domain structure 
1- Amino terminus containing putative Nuclear Export Sequence (NES) 
2- SH3 binding motif 
3- Putative WW binding motif 
4, 8  -  SH2 binding motifs 
5, 7 -   Pleckstrin Homology (PH) domains 
6- Serine Threonine Kinase Interaction Region (STK) 
9-        Coil/turn region, unknown function. 
10-      Leucine zipper motif 
11-     Actin binding regions 
12-     Carboxy terminus, unknown function. 
 



















Figure 2. Results of phosphotryptic mapping analysis of AFAP-110.  
 
A. Recombinant AFAP-110 was phosphorylated with recombinant PKCα in vitro in the 
presence of radiolabeled ATP in a PKC kinase buffer; phosphorylated protein was gel-
purified, eluted out of polyacrylamide and subjected to digestion with       trypsin 
followed by two-dimensional separation of phosphotryptic peptides on a     Thin Layer 
Chromatography (TLC) plate.  
B. Cos-1 cells transiently transfected with AFAP-110 were labeled with radioactive 
orthophosphate for 16 hours and treated with 100nM PMA for 60 minutes prior to cell 
lysis. AFAP-110 was immunoprecipitated from these cell lysates, gel-purified, eluted out 
of polyacrylamide and subjected to digestion with trypsin followed by two-dimensional 
separation of phosphotryptic peptides on a TLC plate. 
C. Cos-1 cells were transiently co-transfected with AFAP-110 and active Src (Src527F), 
and labeled with radioactive orthophosphate for 16 hours prior to cell lysis. AFAP-110 
was immunoprecipitated from these cell lysates, gel-purified, eluted out of 
polyacrylamide and subjected to digestion with trypsin followed by two-dimensional 
separation of phosphotryptic peptides on a TLC plate.  
D. Recombinant AFAP-110 was phosphorylated with recombinant Src kinase in vitro in 
the presence of radiolabeled ATP in an Src kinase buffer; phosphorylated protein was 
gel-purified, eluted out of polyacrylamide and subjected to a digestion with trypsin 
followed by two-dimensional separation of phosphotryptic peptides on a TLC plate.
















































Figure 3. First set of AFAP-110 deletion mutants. Schematic representation of the four 
GST-tagged AFAP-110 deletion mutants missing either SH3 binding motif, potential 
WW binding motif and amino-terminal SH2 binding motif altogether (represented by 
amino acids 62-152), or amino terminal PH domain (represented by amino acids 153-
248), or STK region (represented by amino acids 246-346), or carboxy terminal PH 
domain (represented by amino acids 347- 450). 
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Figure 4.  Confocal actin filament cross-linking assay with full length AFAP-110. 
Rhodamine-labeled filamentous actin was incubated with either non-phosphorylated (A 
and B) or PKCα- phosphorylated (C and D) recombinant AFAP-110 in the actin 
polymerization buffer. The reactions were plated on microscope slides, covered with 
coverslips and analyzed using confocal microscope. Panels A and C represent 10X 
magnification; panels B and D – 63X magnification. 
A                                     B























Figure 5. Confocal actin filament cross-linking assay with AFAP-110∆62-152. 
Rhodamine-labeled filamentous actin was incubated with either non-phosphorylated (A 
and B) or PKCα-phosphorylated (C and D) recombinant AFAP-110∆62-152 in the actin 
polymerization buffer. The reactions were plated on microscope slides, covered with 
coverslips and analyzed using confocal microscope. Panels A and C represent 10X 
magnification; panels B and D – 63X magnification. 
C                                    D























Figure 6. Confocal actin filament cross-linking assay with AFAP-110∆PH1. 
Rhodamine-labeled filamentous actin was incubated with either non-phosphorylated (A 
and B) or PKCα-phosphorylated (C and D) recombinant AFAP-110∆62-152 in the actin 
polymerization buffer. The reactions were plated on microscope slides, covered with 
coverslips and analyzed using confocal microscope. Panels A and C represent 10X 
magnification; panels B and D – 63X magnification. 
A                                     B























Figure 7. Confocal actin filament cross-linking assay with AFAP-110∆STK. 
Rhodamine-labeled filamentous actin was incubated with either non-phosphorylated (A 
and B) or PKCα-phosphorylated (C and D) recombinant AFAP-110∆STK in the actin 
polymerization buffer. The reactions were plated on microscope slides, covered with 
coverslips and analyzed using confocal microscope. Panels A and C represent 10X 
magnification; panels B and D – 63X magnification. 
A                                     B















Figure 8. Confocal actin filament cross-linking assay with AFAP-110∆PH2. 
Rhodamine-labeled actin filaments were incubated with either non-phosphorylated (A) or 
PKCα-phosphorylated (B) recombinant AFAP-110∆PH2 in the actin polymerization 
buffer. The reactions were plated on microscope slides, covered with coverslips and 
analyzed using confocal microscope at 63X magnification. 














Figure 9. Second set of AFAP-110 deletion mutants. Schematic representation of the 
two GST-tagged AFAP-110 deletion mutants missing either first (represented by amino 
acids 249-294) or second (represented by amino acids 295-346) half of STK region. 
∆ 249-294
GST 1 2 3 4    5 7 8 9 10 11 12
∆ 295-346





















Figure 10. Confocal actin filament cross-linking assay with AFAP-110∆249-294. 
Rhodamine-labeled filamentous actin was incubated with either non-phosphorylated (A 
and B) or PKCα-phosphorylated (C and D) recombinant AFAP-110∆249-294 in the actin 
polymerization buffer. The reactions were plated on microscope slides, covered with 
coverslips and analyzed using confocal microscope. Panels A and C represent 10X 
magnification; panels B and D – 63X magnification. 
A                                     B






















Figure 11. Confocal actin filament cross-linking assay with AFAP-110∆295-346. 
Rhodamine-labeled filamentous actin was incubated with either non-phosphorylated (A 
and B) or PKCα-phosphorylated (C and D) recombinant AFAP-110∆295-346 in the actin 
polymerization buffer. The reactions were plated on microscope slides, covered with 
coverslips and analyzed using confocal microscope. Panels A and C represent 10X 
magnification; panels B and D – 63X magnification. 
A                                     B













Figure 12. Third set of AFAP-110 deletion mutants. Schematic representation of the 
two GST-tagged AFAP-110 deletion mutants missing either first (represented by amino 
acids 249-265) or second (represented by amino acids 266-294) quarter of STK region. 
∆ 249-265
GST 1 2 3 4    5 7 8 9 10 11 12
∆ 266-294













Figure 13. Confocal actin filament cross-linking assay with AFAP-110∆249-265. 
Rhodamine-labeled filamentous actin was incubated with either non-phosphorylated (A) 
or PKCα-phosphorylated (B) recombinant AFAP-110∆249-265 in the actin polymerization 
buffer. The reactions were plated on microscope slides, covered with coverslips and 
analyzed using confocal microscope at 40X magnification. 























Figure 14. Confocal actin filament cross-linking assay with AFAP-110∆266-294. 
Rhodamine-labeled filamentous actin was incubated with either non-phosphorylated (A 
and B) or PKCα-phosphorylated (C and D) recombinant AFAP-110∆266-294 in the actin 
polymerization buffer. The reactions were plated on microscope slides, covered with 
coverslips and analyzed using confocal microscope. All panels represent 40X 
magnification.   
A                                     B
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14-3-3 proteins represent a group of small acidic proteins with isoelectric point 
4.5 and molecular weight around 30kDa. These proteins are expressed ubiquitously and 
are known to be present in all species of vertebrates, invertebrates, plants, and fungi (1-
4).  14-3-3 family of proteins includes seven unique isoforms name by Greek letters 
according to their elution order after reverse-phase high-performance liquid 
chromatography: β/α, ζ/δ, η, γ, τ, σ  and  ε (2;5;6). 14-3-3 proteins are highly 
conserved among each other and across different species although they do have   
differences in some regions (5). All 14-3-3 proteins have the ability to dimerize; they can 
form both homo- and heterodimers in vitro and in vivo (4;7). Dimerization occurs via 
hydrophobic interactions between highly conserved residues within amino-terminal parts 
of the molecules (2;5;6). Carboxy-termini of two molecules brought together by 
dimerization create ligand binding amphipathic groove (8;9). Highly conserved residues 
form the inner surface of the binding groove, whereas variable residues create the outer 
surface. This groove may bind either two different molecules or bring together different 
regions of the same protein allowing 14-3-3 to act as scaffolds or allosteric regulators 
(8;10)). The variant residues of the outer surface of the groove may also provide specific 
binding surfaces for different proteins (5). 14-3-3 proteins binding groove is specific for 
either one of the two well-defined structural motifs on target proteins. First of them 
contains phosphoserine (or phosphothreonine) in the center with arginine, serine and 
proline in positions –3, –2, and +2, respectively. Second one is defined as a short amino 
acid sequence containing phosphoserine/phosphothreonine in the center with arginine, 
aromatic residue, basic residue and proline at positions –4, -2, -1, +2 respectively 
(6;9;11). Some 14-3-3 binding sequences are known to contain lysine instead of arginine 
in –3 or –4 position respective to phosphoserine/phosphothreonine  (Dr. Gury Tzivion, 
personal communication). 14-3-3 dimers could bind to several phosphoserine-containing 
motifs on one protein or bring several target proteins together as a consequence of 
binding to conserved motifs found on different proteins. 14-3-3 dimers also may act as 
molecular links   between proteins bound to the conserved groove and ones associated 
with variable outer surface, therefore performing a role of scaffolds that regulate specific 
protein-protein interactions (8).  14-3-3 proteins have been implicated in regulation of 
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serine/threonine kinases such Raf and PKC (12-14). 14-3-3 proteins bind Raf and certain 
PKC isoforms directly and therefore serve to facilitate interactions between these 
signaling proteins (10). Raf is a key protein kinase in mitogen activated protein kinase 
(MAPK) cascade. Raf acts downstream of growth factor receptor and Src-family non-
receptor tyrosine kinases, and Ras, and upstream of MAPK kinase to transmit 
developmental and proliferative signals. 14-3-3 associates with Raf in vivo regardless of 
Raf subcellular localization or activation status (15). Overexpression of 14-3-3 proteins 
has been shown to contribute to Raf activation, although it is clear that 14-3-3 proteins 
unable to activate Raf by themselves (15). Some other reports stated that the nature of 
14-3-3 influence on Raf-1 is inhibitory (16;17). The data on Raf-14-3-3 interaction 
accumulated up-to-date suggests the following model of Raf-14-3-3 interaction: Raf has 
three 14-3-3 binding sequences in its structure. 14-3-3 is bound to cytosolic Raf at 
amino-terminal and carboxy terminal binding sites; this association serves to keep Raf in 
inactive although activatable state. Upon Raf activation by Ras the former undergoes 
translocation to membrane. 14-3-3 protein is displaced from the amino terminal binding 
site on Raf, but it still associates with the carboxy terminal 14-3-3 binding site. Yet 
unidentified kinase come along and phosphorylate the serine in the center of intermediate 
14-3-3 binding site of Raf and 14-3-3 binds to it, stabilizing Raf in active state (9;14). 
14-3-3 therefore has a dual role in Raf regulation.  14-3-3 proteins also have been shown 
to be both PKC substrates and regulatory proteins (12;18). At first it was believed that 
14-3-3 had inhibitory influence on PKC, this conclusion came mostly from the fact that 
PKC inhibitors from brain belong to 14-3-3 family of proteins (19;20). At least three 
possible mechanism of inhibitory influence of 14-3-3 upon PKC have been suggested. 
14-3-3 proteins have been found to contain a stretch of amino acid residues similar to 
PKC pseudosubstrate sequence, which lead to one possible explanation of their 
inhibitory influence on PKC. Another possible mechanism of PKC inhibition by 14-3-3 
proteins arose from the fact that 14-3-3 contains a stretch of amino acid identical to those 
seen in receptors for activated C kinase (RACKs), whose function is to bring active PKC 
to membrane and cytoskeletal structures. 14-3-3 interaction with active PKC therefore 
thought to interfere with its translocation to membrane and therefore inhibit its function 
(2;5). One more possible mechanism came from the observation that 14-3-3 bind to 
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cysteine rich domain of PKC which is responsible for interaction with DAG (5). It was 
postulated that 14-3-3 binding to PKC prevents its activation by DAG (5). Experiments 
conducted by other groups contradict the belief that 14-3-3 inhibit PKC. Studies by Acs 
et al and van der Hoeven et al revealed positive influence of 14-3-3 on PKC activity 
(12;21). The nature of 14-3-3 influence on PKC activity is controversial but nonetheless 
it is apparent that 14-3-3 interacts with PKC. Some 14-3-3 proteins have been shown to 
bind phospholipids; this fact suggests that 14-3-3 family facilitate PKC association with 
cell membrane (7). 14-3-3 may bind to Raf and PKC at the same time, therefore bringing 
Raf to proximity with PKC to ensure phosphorylation of the former by the latter 
(6;10;22).  Recent reports indicate that 14-3-3 proteins may be involved in regulation of 
cytoskeleton organization. 14-3-3 β and γ isoforms have been reported to associate with 
actin and be implicated into rearrangements of cortical actin network (23). Expression of 
dominant negative 14-3-3 analogs in yeast result in disruption of actin cables (24).  
Numerous reports on 14-3-3 that have appeared in recent years indicate that 14-3-
3 proteins act as molecular scaffolds regulating function of signaling proteins by either 
changing thei conformation or by assembling them into multiplayer signaling complexes. 
14-3-3 proteins also appear to play a role in cytoskeletal remodeling. Discovering 
whether 14-3-3 is a binding partner for AFAP-110 may shed light on revealing the new 
insight on the mode of AFAP-110 regulation. 
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II. Materials and methods. 
Expression vectors: pCMV/AFAP-110 and pCMV/AFAP-110/Src527F were 
described in (25;26). pCMV/AFAP-110∆cterm, pCMV/AFAP-110∆lzip, pCMV/AFAP-
110∆44, pCMV/AFAP-110∆Sfu, pGEX-6p-1-AFAP-110 were described in  Qian et al, 
accepted. pEBG-GST-14-3-3 and pEBG-GST-CT-14-3-3 were kindly provided by Dr. 
Gury Tzivion.  





Site directed mutagenesis: pCMV/AFAP-110S548a and pCMV/AFAP-110S569a 
were created by PCR-based site-directed mutagenesis using primers with nucleotide 
mismatches containing desired mutation. Briefly, 20 ng of pCMV/AFAP-110 template 
was mixed with 5 ml of 10X reaction buffer (Stratagene), 125 ng of each primer, 1 ul of 
10 mM dNTP mix (Stratagene), and 2.5 units of Pfu Turbo DNA polymeraze. The 
volume of PCR mix was brought to 50 ml with HPLC grade autoclaved water. The 
reactions were overlaid with 30 ml of mineral oil. The ractions were carried out at 95 
degrees for 30 seconds, and 18 cycles of 95 degrees at 30 seconds, 55 degrees for 1 
minute, and 68 degress for 15 minutes. The reactions were than incubated at 37 degrees 
for 1 hour with 10 units of DpnI restriction enzyme (Roche) to digest the template. 1 ul 
of each PCR reaction was added to 50 ul of Epicurian coli XL-1 Blue supercompetent 
cells and incubated on ice for 30 minutes. The transformation reactions were heat-pulsed 
for 45 seconds at 42 degrees, and placed on ice for 2 minutes. After that 0.5 ml of NZY-
Broth (5 grams of NZ amine, 2.5 grams of yeast extract, 2.5 grams of NaCl were diluted 
in 500 ml of MilliQ water and autoclaved. 6.25 ml of 1 M MgCl2 and 6.25 ml of 1 M 
MgSO4 and 5 ml of a 2M filter-sterilized glucose solution were added to the autoclaved 
broth, and filter-sterilized) preheated to 42 degrees was added to each transformation 
reaction, and the reactions were incubated at 37 degrees with shaking for 1 hour. After 
that the reactions were plated onto 2X Ampicillin LB plates. Cultures from several 
colonies were inoculated for mini-scale DNA preparation, and the extracted DNA was 
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screened either by restriction mapping or DNA sequencing to determine which colonies 
contain pCMV/110 plasmid vector bearing desired substitution. 
Cell culture and transient transfections: Cos-1 cells were maintained in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 5% Fetal Calf 
Serum, 2mM glutamine and 1% penicillin/streptomycin. Cos-1 cells for AFAP-110/14-3-
3 association experiment were transiently co-transfected with AFAP-110 and 14-3-3 
constructs using either Modified Calcium Phosphate-mediated Transfection Procedure or 
lipofectamine 2000 transfection kit. For Modified Calcium Phosphate-mediated 
Transfection Procedure, cells were grown to 60% confluence. 20 µg plasmid DNA for 
single transfection or 15 µg of each plasmid for co-transfection were mixed with 0.5 ml 
of 0.25M CaCl2. 0.5 ml of 2X BES-buffered saline (50mM BES, 280mM NaCl, 1.5 mM 
Na2HPO4x2H2O) was added to DNA dissolved in 0.25M CaCl2, and the mixtures were 
incubated for 20 minutes at room temperature to allow complex formation. After that the 
mixtures were added to Cos cells in a drop wise manner. Cells were then placed into 3% 
CO2 incubator for 16 hours, after which the medium was replaced with fresh growth 
medium and cells were allowed to reach confluence. They were lysed at 60-66 hours 
after transfection in 1x RIPA lysis buffer (1% NP-40, 0.25 % deoxycholate, 150mM 
NaCl, 50mM Tris, pH=7.5 supplemented with protease and phosphatases inhibitors 50 
µg/µl aprotinin, 2mM Sodium Vanadate, 2mM PMSF, 2 mM EGTA, 10 µg/ml 
Leupeptin). For transfection with lipofectamine2000 reagent Cos-1 cells were grown to 
60% confluence on 10 mm cell culture dishes, washed with DMEM supplemented with 
2mM glutamine and overlaid with 6 ml Cos-1 culture medium containing 2 µg of 14-3-3 
plasmid construct, 3 µg of AFAP-110 plasmid construct, and 25 µl lipofectamine 
reagent. In 12-14 hours 6 ml of DMEM supplemented with 20% fetal calf serum, 2mM 
glutamine, and 1% penicillin/streptomycin was added to the cells being transfected. Cells 
were incubated in this medium for 8-10 hours. Then the media containing the 
DNA/lipofectamine mixture was removed and transfected cells were overlaid with 10 ml 
of Cos-7 growth media. Cells were lysed at 36 hours after transfection in either NP-40 
Lysis Buffer (1% NP-40, 150mM NaCl, 50mM Tris, pH=7.5) supplemented with 
protease and phosphatases inhibitors (50 µg/µl aprotinin, 2mM Sodium Vanadate, 2mM 
PMSF, 2 mM EGTA, 10 µg/ml Leupeptin)) or 1XRIPA lysis buffer plus inhibitors. 
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Gluthathione sepharose affinity absorption: GS beads were washed 4 times 
into 1X RIPA lysis buffer. 30 µl of washed beads were added into 1 ml of Cos cell 
lysates co-expressing full length or amino-terminally truncated GST tagged 14-3-3 and 
either wild type or mutant AFAP-110. Pull down reactions were incubated for 2 hours at 
4 degrees with shaking and spun down in tabletop centrifuge; beads were washed twice 
in 1XRIPA and once in 1XTBS, resuspended in 2XLSB, boiled for 5 minutes, and 
subjected to 10% SDS-PAGE followed by Western transfer to PVDF membrane and 
immunoblotting with AFAP-110 reactive antibodies (either 4C3 or F1). In order to 
determine GST-14-3-3 expression levels PVDF membranes were stripped for 30 minutes 
in stripping buffer (3.5 ml 2-ME, 100 ml 10% SDS, 15.6 ml 1M Tris, pH=6.7, 380.85 ml 
milliQ water), at 50 degrees with shaking, washed in TBS-T, blocked in 3% milk and 
stained with anti GST antibody. Pull downs were normalized to GST-14-3-3 expression 
levels. 
Immunoprecipitation: 2 µl polyclonal antibody F1 was added to 1 ml of Cos-1 
cell lysates and the reactions were incubated for 1.5 hours at 4 degrees with shaking. 
After that 30 µl of protein A agarose was added to immunoprecipitation reaction as a 
secondary antibody to pull down F1-AFAP-110 complexes; the reactions were incubated 
for 1.5 hours at 4 degrees with shaking. Complexes were then washed twice with 
1XRIPA and once with 1XTBS, resuspended in 2XLSB, boiled, and subjected to SDS-
PAGE followed by transfer to PVDF membrane for western blotting analysis.   
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III. Results. 
 14-3-3 proteins comprise a family of small acidic adaptor proteins, which 
recognize consensus sites RSXpS/TXP or RXSXpS/TXP. In order for 14-3-3 proteins to 
bind to its target serine or threonine in a position 0 in the center of 14-3-3 binding site 
must be phosphorylated, and arginine (or lysine) in –3 or –4 position must be present for 
14-3-3 binding to occur, whereas S in –2 position and P in +2 position may be 
substituted by any other residue (27).  
AFAP-110 contains twelve potential 14-3-3 binding sequences in its structure 
(table 1). Amino acids stretches 528-534, 45-550 and 660-666 represent the most valid 
candidates to be 14-3-3 binding sites (Dr. Gury Tzivion, personal communication).  
Table 1  
Number Amino acids Potential 14-3-3 binding sequences 
1 37-43 RIQSSKG 
2 279-284 RPSSDG 
3 304-310 RKKSSKT 
4 333-339 KKPSTDE 
5 476-482 RVISTNP 
6 528-534 RTLNSQP 
7 536-541 KPESVS 
8 545-550 RTASNA 
9 565-571 KRLQSKE 
10 660-666 KSGTSSP 
11 672-677 KHRTLE 
12 703-709 RPPSSNN 
Table 2 
AFAP-110 mutants 
used in co-expression 
with 14-3-3 




AFAP-110∆cterm 553-729 9-12 
AFAP-110∆44 593-729 10-12 
AFAP-110∆lzip 554-592 9 
AFAP-110∆Sfu 417-723 5-12 
AFAP-110∆146-343 146-343 2-4 
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AFAP-110 was immunoprecipitated from Cos-1 cell lysates over expressing 
AFAP-110 and subjected to western blotting analysis with anti phospho 14-3-3 binding 
motif antibody. Anti phospho 14-3-3 binding motif antibody was immunoreactive with 
AFAP-110 derived from Cos cell lysates, either non-treated or subjected to 15 minute 
PMA treatment to induce cellular PMA responsive PKC isoforms or co-expressing active 
Src (Figure 1).  These data indicate that, first of all, AFAP-110 may contain one or 
several 14-3-3 binding sequences and second of all, as the antibody is phospho-specific, 
suggest that serine/threonine residues in the middle of 14-3-3 binding sequences must be 
constitutively phosphorylated.  This experiment was repeated three times. 
When we established that AFAP-110 contains 14-3-3 binding sites, we decided to 
find out whether 14-3-3 associated with AFAP-110 in vivo. In order to answer this 
question GST-14-3-3 was co-expressed in Cos cells with AFAP-110. Cells were lysed, 
and 30 µl of gluthathione sepharose beads were used to pull down GST-14-3-3. The 
beads-GST-14-3-3 complexes were boiled and subjected to SDS-PAGE, followed by 
western transfer and staining with anti-AFAP-110 antibody. A 110-kDa band was 
visualized on that blot indicating that AFAP-110 associated with 14-3-3 (figure 2). This 
experiment was repeated three times. 
Next question was to find which region(s) of AFAP-110 is/are responsible for its 
association with 14-3-3. It was proposed to co-express GST-14-3-3 with either one of 
several existing AFAP-110 deletion mutants missing one or more potential 14-3-3 
binding sequences (table 2). The mutant that would fail to associate with 14-3-3 would 
therefore be missing sequence(s) facilitating 14-3-3 association with AFAP-110, and 
would also suggest the possibility of direct interactions between 14-3-3 and AFAP-110. 
 First of all, GST-14-3-3 was co-expressed with either full length AFAP-
110 or truncated version of it missing amino acids 553-729 (AFAP-110∆cterm). AFAP-
110∆cterm lacks five carboxy-terminally located potential 14-3-3 binding sequences. The 
pull down experiments demonstrated that full length AFAP-110 associates with 14-3-3 
whereas carboxy terminally truncated AFAP-110 fails to associate with 14-3-3 (figure 
3). This experiment was repeated twice. 
When we established that AFAP-110 contains 14-3-3 binding sites, we decided to 
find out whether 14-3-3 associated with AFAP-110 in vivo. In order to answer this 
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question GST-14-3-3 was co-expressed in Cos-1 cells with AFAP-110. Cells were lysed, 
and 30 µl of gluthathione sepharose beads were used to affinity absorb GST-14-3-3 from 
the cell lysates. Affinity absorptions were normalized to GST-14-3-3 expression levels. 
The beads-GST-14-3-3 complexes were then washed twice in lysis buffer and once in 
1XTBS buffer, resuspended in 2XLSB, boiled and subjected to SDS-PAGE, followed by 
western transfer and staining with anti-AFAP-110 antibody (F1 or 4C3). A 110-kDa 
band was visualized on the blot indicating that AFAP-110 associated with 14-3-3 in vivo 
(figure 2 - representative of the three experiments). 
Next question was to find which region(s) of AFAP-110 responsible for 
interaction with 14-3-3. Analysis of amino acid sequence of AFAP-110 reveals the 
presence of twelve candidate 14-3-3 target sequences within its structure (table 1). In 
order to determine which sequences facilitate AFAP-110 association with 14-3-3 in vivo 
it was proposed to co-express GST-14-3-3 with either one of several existing AFAP-110 
deletion mutants missing one or more potential 14-3-3 binding sequences (table 2). The 
mutant(s) that would fail to associate with 14-3-3 would therefore be missing 
sequence(s) facilitating 14-3-3 association with AFAP-110, and would also suggest the 
possibility of direct interactions between 14-3-3 and AFAP-110.  First of all, GST-14-
3-3 was co-expressed with either full length AFAP-110 or truncated version of it missing 
amino acids 553-729 (AFAP-110∆cterm). AFAP-110∆cterm lacks four carboxy-terminally 
located potential 14-3-3 binding sequences. The pull down experiments demonstrated 
that full length AFAP-110 associates with 14-3-3 whereas carboxy terminally truncated 
AFAP-110 fails to associate with 14-3-3 (figure 3). This experiment was repeated twice.  
We included into our following experiments gluthathione sepharose pull down 
from cell lysates over expressing GST-Cterm-14-3-3 with full length AFAP-110 as soon 
as we received pEBG-GST-Cterm-14-3-3 plasmid from our collaborator Dr. Gury 
Tzivion. 14-3-3 mutants containing amino-terminal truncation fail to dimerize, and 
therefore in most cases they fail to bind to target proteins for full length 14-3-3. If GST-
Cterm-14-3-3 would associate with AFAP-110 as well as GST-14-3-3, we would 
conclude that AFAP-110 might be one of those few 14-3-3 target proteins, which contain 
high affinity 14-3-3 binding sequences. If GST-Cterm-14-3-3 would fail to associate 
with AFAP-110, we would therefore be able to use it as a negative control in our pull 
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down experiments. Our experiments indicated that GST-Cterm-14-3-3 associates with 
AFAP-110 much weaker than full length 14-3-3 (figures 5,6,7). The presence of 
background band in our experiments may be explained by the dimerization between N-
terminal GST-tags; although GST-facilitated dimerization is much weaker and cannot by 
any means compensate for absence of N-terminal helices of 14-3-3.  
The failure of GST-14-3-3 to pull down AFAP-110∆cterm suggested that the 
carboxy terminal potential 14-3-3 binding sequences of AFAP-110 play an important 
role in 14-3-3-AFAP-110 interactions. The deletion of amino acids 553-729 results in 
disappearance of four carboxy terminal potential 14-3-3 binding sequences (table 2) and 
a possible disruption of potential 14-3-3 binding sequence represented by amino acids 
545-550; this sequence is which is one of the three strongest candidates to be the 14-3-3 
interaction site on AFAP-110 (Dr. Gury Tzivion, personal communication). Therefore 
we have decided to test whether amino acids   545-550 represent 14-3-3 binding site, 
responsible for 14-3-3 association with AFAP-110. In order to determine that serine 548 
was changed to alanine; this amino acid substitution results in inability of this potential 
14-3-3 binding sequence to be phosphorylated and therefore this site can no longer 
facilitate AFAP-110 interactions with 14-3-3. Serine residue 569 in the middle of the 
neighboring amino acid stretch 565-571 was also changed to alanine, and either one of 
the two site-directed mutants were co-expressed with GST-14-3-3 in cultured cells. In 
order to test whether either one or both of these mutants would fail to associate with 14-
3-3 we pull down GST-14-3-3 from the cell lysates and performed western blotting 
analysis with anti-AFAP-110 antibody 4C3 (Fugure4). This experiment indicated that 
AFAP-110s548a mutant associates with AFAP-110 weaker than either wild type or AFAP-
110s569a mutant (figure 5).  Surprisingly, this experiment has shown that AFAP-
110deltacterm, included as a negative control for AFAP-110 association with 14-3-3, 
associates with 14-3-3 better than full length AFAP-110 and any other AFAP-110 
mutant included into this assay (figure 5). This contradicts the earlier data, which 
indicate that AFAP-110delta cterm cannot associate with 14-3-3. Since then we 
performed more experiments to determine whether c-terminally truncated AFAP-110 
fails to associate with 14-3-3. Three out of seven gluthathione sepharose pull down 
assays indicate that AFAP-110delta cterm fails to associate with GST-14-3-3 (figure 3 -
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representative of two experiments, figure5), whereas four out of seven experiments 
demonstrate that AFAP-110 delta cterm associates with 14-3-3 better than wild type 
(figures 4,6,7,8). We also performed gluthathione sepharose pull down assays from the 
cell lysates over expressing GST-14-3-3 (or even GST-Cterm-14-3-3) with wild type 
AFAP-110 or AFAP-110 deletion mutants missing one or several prospective 14-3-3 
binding sequences (table 2).  We failed to get consistent results with these mutants as 
well. For example, in figure 5 we see that AFAP-110∆lzip associates with GST-14-3-3 
better than AFAP-110 full length and any other mutant, and that even GST-Cterm-14-3-3 
strongly interacts with AFAP-110∆lzip, whereas the very next experiment indicates just 
the opposite - that AFAP-110∆lzip fails to associate with 14-3-3 (figure 6).  The same can 
be said about interactions of GST-14-3-3 with any other AFAP-110 deletion mutant used 
in these assays shown in figures 5 through 7. Therefore we have decided to drop this 
project at this point. We have determined that 14-3-3 and AFAP-110 associate in vivo, 
although it is still unclear whether this association is direct or indirect. It remains to be 
determined which sequence(s) within AFAP-110 structure facilitate AFAP-110 
interaction with 14-3-3 in vivo.  
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IV. Discussion. 
 14-3-3 proteins comprise a group of small acidic proteins, which act as adaptor 
proteins in living cells; due to their ability to form dimers they can regulate function of 
signaling proteins by either changing their conformation or bringing several different 
proteins into multi-protein signaling complexes (27). 14-3-3 proteins are expressed 
ubiquitously, and are known to bind to over sixty cellular proteins via well-defined target 
motifs RSXpS/TXP or RXSXpS/TXP containing phosphorylated serine or threonine 
residue in the middle thereby regulating their function (28).  In this work we tried to 
determine whether actin filament associated protein AFAP-110 is a binding partner for 
14-3-3. AFAP-110 is an actin filament cross-linking protein with an intrinsic ability to 
remodel actin in response to Src/PKC signaling; 14-3-3 association with AFAP-110 
could link AFAP-110 to Raf-MAPK cascade or stabilize AFAP-110 interactions with 
PKC in the same manner as 14-3-3 brings PKC and Raf together into close proximity. 
 Western blotting analysis of AFAP-110 with anti-14-3-3 binding site antibody 
suggested that AFAP-110 is a possible binding partner for 14-3-3 (Figure 1). 
Gluthathione sepharose pull down assays from cell lysates co-expressing GST-tagged 
14-3-3 and AFAP-110 indicate the possibility of in vivo association of these two 
proteins.  Analysis of amino acid sequence of AFAP-110 demonstrates that there are 
twelve prospective 14-3-3 binding sequences within AFAP-110 structure (table1). In 
order to determine which sequences facilitate AFAP-110 association with 14-3-3 in vivo 
we co-expressed GST-14-3-3 with either full length AFAP-110 or either one of five 
AFAP-110 deletion mutants (table 2). We were trying to determine which deletion would 
result in inability of AFAP-110 to associate with 14-3-3; AFAP-110 mutant, which 
would fail to associate with GST-14-3-3, would therefore miss 14-3-3 binding site(s) 
responsible for 14-3-3 interactions with AFAP-110. Inability of a deletion mutant to 
associate with 14-3-3 would suggest the possibility of direct interaction between AFAP-
110 and 14-3-3. At first the data was indicating that AFAP-110∆cterm fails to associate 
with 14-3-3, and we thought that one of the four carboxy-terminal potential14-3-3 
binding sequences of AFAP-110 facilitate interactions with 14-3-3. It was also possible 
that the carboxy-terminal truncation of AFAP-110 alters a strong potential 14-3-3 
interaction site delineated by amino acids 545-550, so the AFAP-110 mutant that has 
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serine in the middle of this site substituted by alanine residue was created to test the 
importance of this particular sequence in AFAP-110 interactions with 14-3-3. We also 
made another site-directed mutant of AFAP-110 by substitution of serine residue (s569) 
in the middle of neighboring prospective 14-3-3 binding sequence delineated by amino 
acids 565-571. This is the most amino terminal of four potential 14-3-3 binding sites, 
which are completely missing in AFAP-110∆cterm. We decided to compare effects of 
these two amino acid substitutions on AFAP-110 associations with 14-3-3. GST-14-3-3 
pull down assays have shown that neither one of these mutants fail to associate with 14-
3-3 although GST-14-3-3 associates with AFAP-110s548a weaker than with either wild 
type AFAP-110 or AFAP-110s569a. Therefore, amino acids 545-550 may represent one of 
the pivotal 14-3-3 interaction sequences within AFAP-110 structure, but certainly not the 
only one. More experiments are required to determine the significance of this particular 
sequence in AFAP-110-14-3-3 interactions.  
 Further experiments have demonstrated that AFAP-110 delta cterm interacts with 
GST-14-3-3 better than full length AFAP-110, which did not agree with the previous 
data. In order to determine whether AFAP-110∆cterm associates with 14-3-3 better or 
worse than full length AFAP-110 more gluthathione sepharose affinity absorptions of 
GST-14-3-3 from cell lysates co-expressing GST-14-3-3 and AFAP-110 or AFAP-
110∆cterm or any other existing AFAP-110 deletion mutants were performed. The results 
were controversial for all the deletion mutants used in these experiments; for example, in 
case of GST-14-3-3 and AFAP-110∆cterm co-expressions the results of the three pull down 
assays inducate failure of AFAP-110 cterm to associate with 14-3-3 whereas the results 
of four pull down assays demonstrate that AFAP-110∆cterm associates with 14-3-3 much 
better than full length AFAP-110. It is uncertain at this point whether the loss of c-
terminus, or deletion of leucine zipper or any other region of AFAP-110 (table 2) has 
positive or negative effect on ability of AFAP-110 to associate with 14-3-3 in vivo. The 
controversy of results of our pull down experiments may be explained by the differences 
in phosphorylation level of AFAP-110 at the time when the cells were lysed, as it is 
known that 14-3-3 binding is phosphorylation dependent; serine/threonine 
phosphorylation is also known to induce conformational change of AFAP-110, therefore 
the variations in phosphorylation levels and conformation of AFAP-110 at the time of 
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cell lysis may be responsible for the lack of consistency in our pull down assays. 14-3-3 
proteins are known to interact with over 60 binding partners in living cells (28), and the 
binding of 14-3-3 proteins to their targets does not always occur via interactions of inner 
surface of 14-3-3 binding groove with phosphoserine-containing consensus sites 
RSXpS/TXP or RXSXpS/TXP. For example, 14-3-3 is known to bind to adaptor protein 
IRS-1 in phosphospecific manner despite the fact that IRS-1 contains no 14-3-3 binding 
consensus sequences such as RSXpS/TXP or RXSXpS/TXP (27).  In some cases the 
interaction with target protein may occur on the outer surface of 14-3-3 binding groove 
(9). In the latter case it is unknown which sequences on target proteins facilitate its 
interactions with 14-3-3, and 14-3-3 binding in this case is likely to be phosphorylation-
independent.  
 In conclusion it can be said that our experiments indicated that AFAP-110 
associates with 14-3-3 in vivo, although it still remains unclear whether this association 
is direct or facilitated by one or more of 60 14-3-3 binding partners. In order to 
determine whether AFAP-110 interacts with 14-3-3 directly we would need to perform 
affinity absorption of purified AFAP-110 with purified 14-3-3 and vice versa; for this 
experiment we would need both proteins to be purified from mammalian cells, so they 
would be in proper conformation and contain proper post-translational modifications, 
which will most likely be absent in proteins expressed in bacterial cells. We do not have 
all the necessary equipment to perform this kind of experiment at this time, so this 
project must be postponed until this kind of equipment is available.  
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Figure 1. Cos-1 cells were transiently transfected with AFAP-110 with no treatment 
(lane 1), AFAP-110 with Src527F (lane2), or AFAP-110 along treated with 100nM PMA 
for 1 hour (lane3). AFAP-110 was immunoprecipitated from these cells and subjected to 
SDS-PAGE followed by Western transfer and staining with anti 14-3-3 binding site 
antibody (upper panel). Blot was stripped and reprobed with 4C3 antibody to determine 

















Figure 2. Cos-1 cells were transiently transfected with either GST-14-3-3 alone or 
AFAP-110 alone (lanes 1 and 3 respectively in both panels) or co-transfected with both 
GST-14-3-3 and AFAP-110 (lane 2 in both panels). A. GST-14-3-3 was pulled down 
from cell lysates with gluthathione sepharose beads and subjected to SDS-PAGE 
followed by western blotting with F1 antibody. Pull down assay was normalized to GST-
14-3-3 levels. B. AFAP-110 expression levels in cells lysates used in panel A.  
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Figure 3. Cos-1 cells were transiently transfected with either GST-14-3-3 alone (lane 1 in 
both panels) or co-transfected with GST-14-3-3 with either full length AFAP-110 (lane 2 
in both panels) or AFAP-110∆cterm (lane 3 in both panels). GST-14-3-3 was pulled down 
from cell lysates with gluthathione sepharose beads and subjected to SDS-PAGE 
followed by western blotting with anti-AFAP-110 antibody F1. Pull down assay was 































Figure 4. Upper panel - F1 blot of gluthathione sepharose pull down of GST-14-3-3 from 
Cos-1 cell lysates co-expressing 1 – GST and full length AFAP-110, 2- GST-CT-14-3-3 
and full length AFAP-110, 3- GST-14-3-3 and full length AFAP-110, 4- GST-14-3-3 and 
full length AFAP-110 along with active Src (Scr527F), 5- GST-14-3-3 and AFAP-110∆lzip, 
6- GST-14-3-3 and AFAP-110∆cterm, 7-GST-14-3-3 and AFAP-110s548a, 8- GST-14-3-3 
and AFAP-110s569a. Lower panel represents GST, GST-CT-14-3-3 and GST-14-3-3 

























Figure 5. Upper panels – 4C3 blot of gluthathione sepharose pull down of GST-14-3-3 
from Cos-1 cell lysates co-expressing 1 - GST-CT-14-3-3 and full length AFAP-110, 2- 
GST-14-3-3 and full length AFAP-110, 3- GST-14-3-3 and AFAP-110∆lzip, 4- GST-14-3-
3 and AFAP-110∆cterm,  5- GST-14-3-3 and AFAP-110Sfu∆, 6- GST-14-3-3 and AFAP-
110∆44, 7- GST-14-3-3 and AFAP-110s548a, 8- GST-14-3-3 and full length AFAP-110 
along with active Src (Scr527F), 9- rainbow weight markers, 10- GST-CT-14-3-3 and 
AFAP-110∆lzip, 11- GST-CT-14-3-3 and AFAP-110∆cterm,  12- GST-CT-14-3-3 and 
AFAP-110Sfu∆, 13- GST-CT-14-3-3 and AFAP-110∆44. Lower panels represent GST-14-
























Figure 6. Upper panel - 4C3 blot of gluthathione sepharose affinity absorption of GST-
14-3-3 from Cos-1 cell lysates co-expressing 1 – GST and full length AFAP-110, 2- 
GST-CT-14-3-3 and full length AFAP-110, 3- GST-14-3-3 and full length AFAP-110, 4- 
GST-14-3-3 and AFAP-110∆lzip, 5- GST-14-3-3 and AFAP-110∆cterm,  6- GST-14-3-3 and 
AFAP-110∆44. Lower panels represent GST, GST-14-3-3 or GST-CT-14-3-3 levels to 
which the affinity absorption assays were normalized. 
 



















Figure 7. Upper panel - 4C3 blot of gluthathione sepharose affinity absorption of GST-
14-3-3 from Cos-1 cell lysates co-expressing: 1 - GST-CT-14-3-3 and full length AFAP-
110, 2- GST-14-3-3 and full length AFAP-110, 3- GST-14-3-3 and AFAP-110∆lzip, 4- 
GST-14-3-3 and AFAP-110∆cterm, 5- GST-14-3-3 and AFAP-110Sfu∆, 6- GST-14-3-3 and 
AFAP-110∆146-343, 7 - GST-14-3-3 and AFAP-110s548a, 8- GST-14-3-3 and AFAP-
110∆44, 9- GST-14-3-3 and AFAP-110s569a, 10 –GST-14-3-3 and full length AFAP-110 
along with active Src (Scr527F). Lower panels represent GST-14-3-3 and GST-CT-14-3-3 



























Figure 8. Cos cells were co-transfected with GST-CT-14-3-3 and AFAP-110 (lanes 1), 
GST-14-3-3 and AFAP-110 (lanes2) or GST-14-3-3 and AFAP-110∆cterm. A. Western 
blots of gluthathione sepharose affinity absorption of GST-CT-14-3-3 or GST-14-3-3 
from Cos cell lysates. Upper panel represents 4C3 western blot; lower panel shows the 
same blot as in upper panel striped and reprobed with anti-GST antibody to visualize CT-
14-3-3 and 14-3-3 levels. B. Western blot for expression levels of AFAP-110 (upper 
panel, 4C3 antibody staining) and GST-CT-14-3-3 and GST-14-3-3 (lower panel, anti-
GST antibody staining). 
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AFAP-110 was discovered in late eighties as a protein that associates with active 
Src in v-Src-transformed chicken embryo fibroblast cells (1). AFAP-110 co-localizes 
with actin stress fibers as well as cortical actin cytoskeleton in normal cells and with actin 
rosettes in Src transformed cells.  As AFAP-110 is hyperphosphorylated in response to 
co-expression with active Src and also has the ability to associate with this non-receptor 
tyrosine kinase, it was proposed that AFAP-110 might be an effector protein for Src that 
remodels actin cytoskeleton in response to Src activation by extracellular stimuli (2).  
AFAP-110 contains several protein-protein interaction modules, which enable this 
protein to bind to other proteins such as filamentous actin and cellular kinases Src and 
PKC. AFAP-110 also possesses the ability to multimerize via carboxy-terminal leucine 
zipper motif. The deletion of carboxy terminal leucine zipper motif enables AFAP-110 to 
disorganize actin cytoskeleton resulting in a phenotype resembling the consequences of 
active Src over expression characterized by actin filament repositioning into actin 
rosettes. AFAP-110 therefore possesses an intrinsic ability to remodel actin cytoskeleton.  
In recent years it has been determined that AFAP-110 is an actin cross-linking 
protein, and that actin cross-linking ability of AFAP-110 is regulated by serine/threonine 
phosphorylation (Qian et al, accepted).  AFAP-110 actin cross-linking properties are 
dependent on its multimerization status; non-phosphorylated AFAP-110 is thought to 
exist in a form of large multimeric complexes cross-linking filamentous actin into a 
lattice of loosely interconnecting actin fibers whereas phosphorylated AFAP-110 is 
thought to exist only in a form of dimers and cross-link actin filaments into a network of 
short bundles (Qian et al, accepted). AFAP-110 ability to self-associate is regulated by 
serine/threonine phosphorylation in PKC dependent manner (Baisden and Flynn, 
unpublished data). Therefore it became important to identify serine and threonine 
residues within AFAP-110 structure phosphorylation of which induces changes in AFAP-
110 conformation resulting in altered mode of self-association and consequently in 
enhancement of actin cross-linking properties of AFAP-110. Identification of functional 
phosphorylation sites of AFAP-110 was an objective of the first project, described in 
chapter 2 of this thesis. 
Firstly, we performed phosphotryptic-mapping analysis of AFAP-110 either 
recombinant phosphorylated by PKCα in vitro or AFAP-110 derived from radio labeled 
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cultured cells either expressing active Src or treated with PKC activator PMA. We 
determined that PKCα phosphorylates AFAP-110 on multiple residues in vitro and also 
that two of the fragments on the maps of in vivo derived AFAP-110 are likely to be 
products of PKC dependent phosphorylation in vivo.   
Secondly, we performed PCR-based deletional mutagenesis to determine which 
domains of AFAP-110 are the most likely to contain functional phosphorylation sites as 
the analysis of AFAP-110 amino acid sequence revealed over twenty PKC consensus 
phosphorylation sequences. Confocal actin filament cross-linking assays developed by 
Qian and colleagues (Qian et al, accepted) were used as a test for AFAP-110 
phosphorylation-regulated function. Wild type AFAP-110 cross-links actin filaments into 
loose lattices when non-phosphorylated, but, once it is phosphorylated, this protein 
arranges actin filaments into more efficiently cross-linked actin filament aggregates. In 
our experiments with AFAP-110 deletion mutants we were looking whether any of them 
would fail to display increase in actin cross-linking efficiency upon phosphorylation. 
Such a mutant was found; it is an AFAP-110 deletion mutant missing amino acids 249-
346 comprising Serine Threonine Kinase Interaction  (STK) region.  
There are nine prospective PKC phosphorylation sites within STK region, 
therefore two more deletional mutants were created, each missing either first (amino 
acids 249-294) or second half (amino acids 295-346) of STK region. The deletion of 
amino terminal half of STK region abrogated PKCα-dependent increase in actin filament 
cross-linking efficiency of AFAP-110, whereas the deletion of carboxy-terminal half of 
STK region did not have any effect on PKCα-dependent increase in actin filament cross-
linking efficiency of AFAP-110. Therefore we draw a conclusion that functional 
phosphorylation sites of AFAP-110 must reside within amino acid stretch 249-294. There 
are six candidate sites in this region; therefore we created two more deletion mutants 
missing either first (amino acids 249-265) or second (amino acids 266-294) quarter of 
STK region to narrow down to the region containing not more than four potential sites. 
Our data suggests that four serine residues within amino acid stretch 266-294 are the 
most likely candidates to be functional PKC phosphorylation sites responsible for 
phosphorylation-regulated AFAP-110 function. These residues are being altered by site-
directed mutagenesis either all at once or in pairs. Future experiments will determine 
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whether some or all of these serine residues are AFAP-110 functional phosphorylation 
sites. Phosphotryptic mapping analysis will determine if these serine residues are 
phosphorylated in vitro versus in vivo. The mutants will also be tested in in vitro actin 
filament cross-linking assays to determine whether a loss of all the four serine residues or 
either serine pair would result in inability of PKCα to enhance actin cross-linking 
properties of AFAP-110. These mutants will also be expressed in cultured cells to 
determine whether any of them would block the effects of active PKC on actin 
cytoskeleton. 
The objective of the second project described in chapter three was to determine 
whether AFAP-110 is a binding partner for 14-3-3. 14-3-3 proteins are a family of small 
acidic proteins originally discovered as brain proteins in 1967 (Moore and Perez, 1967). 
By now it is known that these proteins are expressed ubiquitously and are common to 
every known organism studied up to date. They have no catalytic function of their own 
but nevertheless play an important role in cellular signal transduction pathways because 
of their ability to act as scaffolds and/or allosteric regulators for signaling proteins due to 
their ability to form dimers (3). 14-3-3 proteins dimerize via interaction between their 
amino terminal parts and bind to target proteins via highly conserved carboxy terminally 
located binding grooves, which are know to recognize specific target sequences in 
phosphorylation-dependent manner. These target sequences usually have phosphorylated 
serine or threonine in the middle, position 0, with basic amino acid in position –3 or –4 
and proline in position +2. The basic amino acid in –4 or –3 position in most case is 
arginine but sometimes it can be substituted by lysine. Basic amino acid in position –4 or 
–3 as well as phosphorylation of serine/threonine in position 0 are required for 14-3-3 
binding to occur, whereas proline in position +2 is preferred but no absolutely required. 
There are certain preferences in other positions surrounding the central phosphorylated 
serine/threonine but neither of them as crucial as the presence of basic residue in position 
–4 or –3 or requirement for phosphorylation of the central serine/threonine. Binding 
groove of 14-3-3 proteins in fact was the first serine/threonine phosphorylation-binding 
domain discovered and nowadays it remains the best-studied phospho-serine/threonine 
binding module. 
 100
14-3-3 binds a wide variety of proteins participating in different cellular 
pathways, among which are serine/threonine kinases Raf, PKC and Bcr, cellular adaptor 
proteins IRS-1, Gab1, and p66Shc, apoptotic protein Bad, cdc25C phosphatase and others 
(4;5) We proposed to determine whether AFAP-110 would be a binding partment for 14-
3-3.  
First of all, by Western blotting analysis of cellular AFAP-110 with phospho-
specific anti-14-3-3 binding site antibody we determined that AFAP-110 contains 14-3-3 
binding sequence(s).  By the next experiment demonstrated that 14-3-3 and AFAP-110 
are associated in vivo, although it remained unknown whether the two proteins bind to 
each other directly or via some other cellular adaptor. Analysis of AFAP-110 amino acid 
sequence revealed the presence of twelve potential 14-3-3 binding sequences in its 
structure, three of which were better candidates comparing to the remaining nine 
according to Dr. Gury Tzivion (personal communication).  
When we have shown that AFAP-110 associates with 14-3-3 in vivo, we have 
decided to find out which regions of AFAP-110 make this interaction possible. It was 
decided to co-express different AFAP-110 deletion mutant missing one or several 
potential 14-3-3 binding sequences in order to determine which deletion if any results in 
abrogation of AFAP-110 association with 14-3-3. The mutant that would fail to associate 
with 14-3-3 in vivo would do so either because it lacks important 14-3-3 binding site(s) or 
simply because deletion of a certain region results in altered AFAP-110 conformation so 
that 14-3-3 can no longer associate with AFAP-110. Once such a mutant was found, we 
would have used PCR-based site directed mutagenesis to substitute serine/threonine 
residue(s) in the middle of important 14-3-3 binding site(s) to alanines to determine 
whether AFAP-110 inability to associate with 14-3-3 is a result of disappearance of 
pivotal 14-3-3 binding sequence or merely the consequence of conformational change. If 
we would find that the disappearance of 14-3-3 binding site(s) as a result of deletion or 
site directed mutation is responsible for abrogation of 14-3-3 association with 14-3-3, we 
would have, first of all, found which 14-3-3 binding sequences within AFAP-110 
structure make 14-3-3-AFAP-110 interactions possible, and, would get a strong 
suggestion that 14-3-3 binds AFAP-110 directly.  
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Either one out of several AFAP-110 deletion mutants were co-expressed with 
GST-14-3-3 in cultured cells, and gluthathione sepharose affinity absorption of GST-14-
3-3 followed by western blotting with anti-AFAP-110 antibodies were performed in order 
to determine which AFAP-110 mutant fails to associate with 14-3-3. Neither of AFAP-
110 deletion mutants used in our experiments consistently failed to associate with 14-3-3. 
This may occur due to a number of reasons. First of all, association of AFAP-110 with 
14-3-3 may be indirect, and there is a third, yet unidentified protein that facilitated 
AFAP-110 interactions with 14-3-3. Second of all, 14-3-3 does not always bind to well 
defined RSXpSXP or RXXXpSXP sequences. 14-3-3 is known to bind in 
phosphorylation-dependent manner to proteins such as IRS-1, vimentin, Wee1, and IGF-
I, although neither of these proteins contains either one of well-defined 14-3-3 binding 
sequences (Tzivion and Avruch, 2001). 14-3-3 may also bind to target proteins via 
variable outer surface of binding groove.  
Thus, we have determined that AFAP-110 associates with full length 14-3-3 in 
vivo, whereas association of monomeric 14-3-3 with AFAP-110 is very weak, almost at 
the background level. It still remains to be determined whether AFAP-110 and 14-3-3 
associate directly and, if yes, whether 14-3-3 interactions with AFAP-110 are 
phosphorylation dependent and facilitated by any of the twelve conventional sequences 
defined as RSXpSXP or RXXXpSXP.  
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